





Review

# Application of Noninvasive Vagal Nerve Stimulation to Stress-Related Psychiatric Disorders

James Douglas Bremner <sup>1,2,3,\*</sup> , Nil Z. Gurel <sup>4</sup> , Matthew T. Wittbrodt <sup>1</sup>,  
Mobashir H. Shandhi <sup>4</sup> , Mark H. Rapaport <sup>1</sup>, Jonathon A. Nye <sup>2</sup>, Bradley D. Pearce <sup>5</sup>,  
Viola Vaccarino <sup>5,6</sup>, Amit J. Shah <sup>3,5,6</sup> , Jeanie Park <sup>3,7</sup>, Marom Bikson <sup>8</sup> and Omer T. Inan <sup>4,9</sup>

- <sup>1</sup> Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA; mwittbr@emory.edu (M.T.W.); mark.h.rapaport@emory.edu (M.H.R.)  
<sup>2</sup> Department of Radiology, Emory University School of Medicine, Atlanta, GA 30322, USA; jny@emory.edu  
<sup>3</sup> Atlanta VA Medical Center, Decatur, GA 30033, USA; ajshah3@emory.edu (A.J.S.); jeanie.park@va.gov (J.P.)  
<sup>4</sup> School of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA; nil@gatech.edu (N.Z.G.); mobashir.shandhi@gatech.edu (M.H.S.); omer.inan@ece.gatech.edu (O.T.I.)  
<sup>5</sup> Department of Epidemiology, Rollins School of Public Health, Atlanta, GA 30322, USA; bpearce@emory.edu (B.D.P.); lvaccar@emory.edu (V.V.)  
<sup>6</sup> Department of Medicine, Cardiology, Emory University School of Medicine, Atlanta, GA 30322, USA  
<sup>7</sup> Department of Medicine, Renal Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA  
<sup>8</sup> Department of Biomedical Engineering, City University of New York, New York, NY 10010, USA; bikson@ccny.cuny.edu  
<sup>9</sup> Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA  
\* Correspondence: jdbremn@emory.edu

Received: 18 June 2020; Accepted: 3 September 2020; Published: 9 September 2020



**Abstract:** Background: Vagal Nerve Stimulation (VNS) has been shown to be efficacious for the treatment of depression, but to date, VNS devices have required surgical implantation, which has limited widespread implementation. Methods: New noninvasive VNS (nVNS) devices have been developed which allow external stimulation of the vagus nerve, and their effects on physiology in patients with stress-related psychiatric disorders can be measured with brain imaging, blood biomarkers, and wearable sensing devices. Advantages in terms of cost and convenience may lead to more widespread implementation in psychiatry, as well as facilitate research of the physiology of the vagus nerve in humans. nVNS has effects on autonomic tone, cardiovascular function, inflammatory responses, and central brain areas involved in modulation of emotion, all of which make it particularly applicable to patients with stress-related psychiatric disorders, including posttraumatic stress disorder (PTSD) and depression, since dysregulation of these circuits and systems underlies the symptomatology of these disorders. Results: This paper reviewed the physiology of the vagus nerve and its relevance to modulating the stress response in the context of application of nVNS to stress-related psychiatric disorders. Conclusions: nVNS has a favorable effect on stress physiology that is measurable using brain imaging, blood biomarkers of inflammation, and wearable sensing devices, and shows promise in the prevention and treatment of stress-related psychiatric disorders.

**Keywords:** PTSD; stress disorders; posttraumatic; depressive disorders; vagus nerve; VNS; sympathetic; inflammation; interleukin-6; vagal nerve stimulation; interferon; stress


## 1. Introduction

Stress-related psychiatric disorders, including depression and posttraumatic stress disorder (PTSD), are important public health problems. Early life stress increases the risk of development of depression in adulthood [1,2], and stressful life events are associated with an increased risk for depressive episodes [3], while PTSD requires exposure to a traumatic stressor as part of the diagnosis [4]. At any given time, 10% of the United States population meets the criteria for major depression or other mood disorders based on Diagnostic and Statistical Manual (DSM) criteria [5], with an annual cost of lost productivity of USD 44 billion [6]. Similarly, PTSD affects 6% of the population at some time in their lives [7]. The cost of treating PTSD and comorbid depression in soldiers returning from the wars in Iraq and Afghanistan has been estimated to be USD 6.2 billion [8], and since PTSD affects a larger total number of civilians in the United States than military personnel, the costs for society as a whole are likely much higher [9]. The most common cause of PTSD in women is sexual abuse and assault in childhood, while, for men, it is physical assault [10]. On average, women have higher occurrence of PTSD compared to men in the civilian population [11,12]. PTSD is characterized by intrusive thoughts, nightmares, avoidance, emotional blunting, negative cognitions, hypervigilance, and hyperarousal [13]. Depression is associated with depressed mood, loss of appetite, decreased psychomotor activity, and, in extreme cases, suicidal ideation. Other symptoms, such as poor sleep and concentration, negative cognitions, loss of interest in things, and anhedonia, are common to both conditions. In fact, there is a degree of comorbidity between the two conditions [14–19]. Furthermore, patients with comorbid disorders have a worse clinical course, with, for instance, a higher risk of suicidal ideation [20,21].

The standard of care for both PTSD and depression includes psychotherapy and/or medication [22,23]. Psychotherapy treatments for PTSD, however, have dropout rates as high as 50%, which limit their applicability [24,25]. First-line medication treatments for stress-related psychiatric disorders involves the Selective Serotonin Reuptake Inhibitor (SSRI) antidepressants [26,27]. However, as highlighted by a report from the Institute of Medicine, there is not sufficient evidence to conclude that they are effective for PTSD [28]. In fact, only one-third of those suffering from PTSD are able to achieve full remission with the current standard of care [26]. Similar limitations exist for treatment of major depression. As illustrated by the STAR\*D study, only one-third of patients with major depression remitted to first-line therapy with antidepressants and only about two-thirds of patients met remission criteria after multiple algorithms that included psychotherapy, switching classes, and multiple heroic augmentation trials [29]. Given limitations of current treatment options, new paradigms are clearly needed for the management of stress-related psychiatric disorders.

## 2. Physiology of the Vagus Nerve

The vagus nerve represents a unique window between central functions of the brain and peripheral organ function that may be a promising target for treatment interventions for stress-related psychiatric disorders. The vagus has cell bodies in the brainstem and motor fibers that modulate peripheral organ function, as well as sensory fibers that relay information about peripheral organs to the brain (Figure 1). The efferent function of the vagus nerve primarily modulates parasympathetic nervous system function in the periphery and therefore acts as a counterbalance to the sympathetic nervous systems. Afferent vagal nerve fibers relay sensory activity of the visceral organs to the brain through the nucleus tractus solitarius (NTS) in the medulla oblongata and the locus coeruleus in the pons, with relays to areas of the brain involved in the modulation of emotion and the stress response, including the amygdala, insula, hippocampus, and anterior cingulate/prefrontal cortex [30].



**Figure 1.** Model of effects of transcutaneous Vagus Nerve Stimulation (VNS) on physiological function. Stimulation of the vagus nerve in the neck as it passes through the carotid sheath (transcutaneous cervical VNS (tcVNS)) or in the ear (transcutaneous auricular VNS (taVNS)) activates the Nucleus Tractus Solitarius (NTS) in the brainstem, which has projections to other key brainstem nuclei containing cell bodies for neurotransmitters, including the locus coeruleus (LC), site of norepinephrine (NE), pedunculopontine nucleus (PPN) for acetylcholine (ACh), and raphe nucleus (RN) for serotonin (5-HT), and the reticular activating system (RAS). These regions, in turn, originate pathways to multiple brain areas involved in modulation of fear and emotion, as well as memory and neuroplasticity, including the anterior cingulate, hippocampus, amygdala, and cortex (including insula). Vagal efferents project to peripheral cardiovascular, autonomic, and inflammatory pathways. The vagus also projects information from the periphery back to the brain through afferents.

### 3. Neurobiology of Stress-Related Psychiatric Disorders

The vagus nerve modulates circuits and systems that underlie the symptoms of stress-related psychiatric disorders. The neurobiology of stress-related psychiatric disorders includes alterations in brain regions involved in memory and the stress response [31–34]. The hypothalamic–pituitary–adrenal (HPA) axis plays an important role in stress, and dysregulation of this system is associated with PTSD

and depression [35–42] and is potentially modifiable by the vagus nerve [43–45]. Norepinephrine and sympathetic function are also involved in stress-related psychiatric disorders, with elevations typically seen in both patients with PTSD and depression, in addition to dysregulation of the peripheral autonomic nervous system [46–57].

Abnormalities of the inflammatory function are also associated with PTSD and depression [58,59]. Interleukin 1B (IL1B), IL-6, Tumor Necrosis Factor (TNF), Interferon gamma (IFN- $\gamma$ ), and C-Reactive Protein (CRP) are elevated in PTSD [60], and several of these immune mediators are increased after acute stress [61,62]. Patients with cardiovascular disease and the diagnosis of PTSD had an enhanced IL6 response to stressful tasks (“mental stress”) compared patients without PTSD [63], with similar findings in individuals with early life stress, and vulnerability to depression [60,63,64]. Increased levels of proinflammatory cytokines and increased reactivity of the Nuclear Factor Kappa-light-chain-enhancer of activated B cells (NF- $\kappa$ B) system have been observed repeatedly in a subset of patients with depression [58,65]. Studies show that the stress-induced release of catecholamines acts through adrenergic receptors to activate NF- $\kappa$ B, and subsequently stimulates the release of cytokines, including IL-6 [66]. Interpersonal stress may have led to activation of inflammatory processes in response to imminent personal injury and therefore had survival value in evolution [58,67]. A recent meta-analysis showed that the statistically strongest findings in PTSD were for IL-6 and IFN- $\gamma$  [68]. Elevations in IFN- $\gamma$  and IL-6 are associated with decreases in tryptophan, the precursor of serotonin, a key neurotransmitter underlying the neurobiology of both depression and PTSD [69–71]. Increases in IL-6 also result in increases in kynurenine, which has been linked to suicide and depression [72], and quinolinic acid, which enhances glutamatergic transmission with associated decreases in brain derived neurotrophic factor (BDNF) in the hippocampus, which may be involved in symptoms of PTSD and depression and mechanisms of action of antidepressants [73–76]. These studies have shown the importance of intervention in the psychobiology of PTSD and depression, which potentially can be done with tcVNS.

Alterations in cell-mediated immunity in PTSD may be relevant to the mechanisms of action of tcVNS. Cell-mediated immunity utilizes T cells, including CD8+ cytotoxic cells that lyse cells harboring microbes and CD4+ cells that produce cytokines and activate phagocytes that engulf and kill microbes. These latter cells differentiate into Th1 and Th2 subsets, as well as Th17 subsets. T helper cell differentiation is partly controlled by cholinergic neurotransmission [77] and dysregulation of this system is associated with PTSD [78,79]. Glucocorticoids, including cortisol, inhibit immune function and lower concentrations of cortisol in patients with PTSD [41,80], and could result in enhancement of Th1 cell function [78,79] with an associated increase in IFN- $\gamma$ . Studies have shown enhanced cell-mediated immunity in PTSD patients [81] and delayed-type hypersensitivity (DTH) reactions that are consistent with an enhancement of Th1 response and thus increased IFN- $\gamma$  [82]. Other studies have linked DTH responses to elevated IFN- $\gamma$  [83] and have shown increased IFN- $\gamma$  in PTSD [68,84,85]. Vagus nerve stimulation activates T cells that produce acetylcholine, and by binding to the alpha-7 subunit of the cholinergic receptor, they inhibit NF- $\kappa$ B [86], and, based on our studies, IFN- $\gamma$  [87]. VNS also inhibits High Mobility Group Box 1 protein (HMGB1), a proinflammatory master mediator, which is increased in PTSD and is modifiable by VNS [88,89]. These studies have shown several targets for modulation of immune function by vagal nerve stimulation in the treatment of stress-related psychiatric disorders.

Altered neuropeptid function is another target for treatment intervention for stress-related psychiatric disorders [33]. Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide that regulates and integrates adaptive responses to stress [90]. A growing body of literature has pointed to dysregulation of PACAP along with its selective PAC1 receptor in PTSD [90,91]. Elevated PACAP levels were associated with increased PTSD symptoms in females with PTSD [91]. In other studies, PAC1 receptor levels correlated with increased startle response [92,93], a marker of PTSD [94–96]. PACAP plays an important role in physiological stress responses, including those mediated by the sympathetic and parasympathetic nervous system [97]. PACAP distribution in brain areas involved in stress and

emotion, including the hypothalamus, bed nucleus of the stria terminalis, and amygdala, suggests PACAP's involvement in limbic, autonomic, and neuroendocrine functions [98,99]. These systems are also regulated by the vagus nerve, an effect possibly mediated by PACAP.

#### 4. Neuromodulation for Stress-Related Psychiatric Disorders

Neuromodulation represents a promising new paradigm for the treatment of stress-related psychiatric disorders [100]. Neuromodulation involves the use of electricity, magnetism, vibration, or ultrasound actuation to modulate neural function [101]. Forms of neuromodulation that have been applied to psychiatry include electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), transcranial Direct Current Stimulation [102], and Vagal Nerve Stimulation (VNS) [103–107]. Electrical stimulation treatments show promise for the treatment of stress-related psychiatric disorders since they may act through effects on the underlying neurobiology of these disorders [103,104,106,108,109].

Electroconvulsive therapy (ECT) is one of the most effective treatments for patients with treatment-refractory major depression [110]. ECT involves the application of electrical currents to the skull while patients are under anesthesia with the goal of inducing a seizure with associated multiple firing of neurons felt to lead the therapeutic effect seen after multiple treatments [111]. ECT has an 80% response rate, which is a better response rate than for medications [110]. Some studies have suggested that ECT may be more effective in elderly depressed patients [112]. Predictors of good response include low Vitamin B-12 and folate levels and elevated homocysteine (all of which have been linked to depression) [113]. ECT may induce mechanisms which, as reviewed below, have been posited for VNS, and which are common to other successful antidepressant treatments, including modulation of excitatory amino acid transmission and promotion of neurogenesis in the hippocampus [75] and modulation of brain function in the medial prefrontal cortex [114]. ECT results in profound hemodynamic changes including bradycardia, followed by tachycardia and hypertension, as well as increased complication rates, can occur in patients with cardiovascular disease [111]. In spite of relative safety, many patients are hesitant to use ECT due to inconvenience and fear of side effects.

VNS is an electrical stimulation treatment that, in its implantable form, has been shown to be efficacious in the treatment of epilepsy [115–120] and treatment-refractory major depression [121–132], leading to approval by the Food and Drug Administration (FDA) for the treatment of these conditions [133]. VNS, which is currently approved for depression, involves surgical implantation with direct electrical stimulation of the vagus nerve [124,134,135].

VNS has a number of effects on brain circuits and systems that are likely beneficial for stress-related psychiatric disorders. In experimental models of PTSD, vagus nerve stimulation enhanced extinction of conditioned fear and reduced PTSD-like symptoms [136,137]. Thus, studies suggest that VNS is potentially useful for stress-related psychiatric disorders.

VNS has effects on autonomic nervous system function that are likely beneficial for stress-related psychiatric disorders [138,139]. VNS improves autonomic dysfunction, reducing sympathetic and enhancing parasympathetic tone [140–143]

VNS has other effects, including the modulation of fear circuits [137,144,145], induction of neural plasticity [140], enhancement of memory and cognition [130,146–156], and enhancement of central neurotransmitter function including norepinephrine [157,158]. VNS also reduces inflammatory function [159–165]. These findings suggest that VNS may be useful for stress-related psychiatric disorders characterized by central neurotransmitter and peripheral autonomic dysfunction, enhanced inflammation, and impairments in learning and memory [46,47,49–54,166].

#### 5. Vagus Nerve and Neuroplasticity

In addition to efferent fibers, the vagus has afferent fibers that modulate central brain function. Effects of the vagus on neural function include both inhibition of cortical spreading depression [167], as well as effects on brain amino acids, neurotransmitters, and metabolites [168–170]. The vagus also has effects on neural plasticity, as evidenced by enhancement of recovery following cerebral



hemorrhage with vagal nerve stimulation [171]. Pairing of vagal nerve stimulation with an auditory tone was beneficial in an animal model of tinnitus, a disorder involving ringing in the ears, an effect mediated through enhancement of neural plasticity in relevant areas of the brain [172–175]. The vagus enhances neural plasticity after stroke, with beneficial effects both for the recovery of cognitive function [176], as well as motor movement when paired with training in successful motor movements [177–180]. The enhancement of new learning and memory following stimulation of the vagus [149,181] probably occurs through enhancement of long term potentiation (LTP) in the hippocampus [182]. The vagus also modulates fear circuits in the brain in a way that promotes adaptive stress responses [46,136,137,144,183]. In addition to its effects on the brain, the vagus promotes recovery following cardiovascular events in animal models [139,184–186].

## 6. Neural Circuits in Stress-Related Psychiatric Disorders and Vagal Nerve Stimulation

Understanding neural circuits in stress-related psychiatric disorders is important for designing new treatments such as VNS that can target these underlying neurobiological disturbances [187,188]. A network of brain areas, including the hippocampus, amygdala, insula, and medial prefrontal cortex (including anterior cingulate), have been implicated by us and others in the pathophysiology of stress-related psychiatric disorders [34]. The hippocampus, which plays a critical role in declarative (or explicit) memory, is very sensitive to stress [75,189–192]. These effects are reversible with treatment with antidepressants or behavioral interventions like running [73,75,76]. Studies in patients with both PTSD and depression have shown alterations in memory function and reduction of hippocampal volume [193–197]. The amygdala is involved in the processing of emotional stimuli and emotional memory, and plays a critical role in the acquisition of fear responses [198]. The medial prefrontal cortex/anterior cingulate has been implicated in the appraisal and regulation of emotions, and inhibition of the amygdala function represents the mechanism of extinction [199]. Brain imaging studies have implicated the medial prefrontal cortex/anterior cingulate in PTSD [200–215] and depression [216–218]. An increase in function in PTSD is observed in insula [205,209,219] and increased amygdala function is associated with both PTSD [204,205,213,215,220–237] and depression [238–241]. Treatment is associated with changes in these brain regions for both PTSD [34,242–247] and depression [240,241,248–252]. As reviewed below, similar studies have been performed looking at neural circuits and systems response in depression [253–259], and our group has initiated studies using High-Resolution Positron Emission Tomography (HRPET) to assess neural correlates of treatment response in PTSD [260].

## 7. Noninvasive Vagal Nerve Stimulation: Safety and Reliability

Recently, devices have been developed for noninvasive stimulation of the vagus nerve [261]. Noninvasive Vagal Nerve Stimulation (nVNS) devices include transcutaneous auricular VNS (taVNS), which target the auricular branch of the vagus in the ear (with best results at the cymba conchae and tragus) [262], and transcutaneous cervical VNS (tcVNS), which act on the cervical branch as it passes through the carotid sheath in the neck [100]. These devices have been shown to be safe and effective and to reliably and predictably stimulate the vagus nerve in human subjects [263,264]. Vagal somatosensory evoked potentials associated with vagal afferent activation have been reported for both implanted VNS and noninvasive VNS devices used through the neck or ear [265]. Studies using evoked potentials have shown that nVNS reliably stimulates the vagus nerve in humans and anesthetized dogs [141,266–268]. Studies in humans using electroencephalography (EEG) measurements at scalp sites A1-Cz showed that tcVNS and taVNS both result in a predictable and reproducible P1 N1 P2 N2 pattern with biphasic peaks at 3 ms (P1, N1), followed by a large stimulation artifact and large biphasic peaks (P2, N2) at 10 ms that matches the pattern seen with implanted VNS [265,266,268]. Functional brain imaging studies of healthy human subjects with nVNS, including both taVNS [262,269,270] and tcVNS [271], showed the characteristic pattern of neural response of brain areas known to be connected to the Nucleus Tractus Solitarius (NTS), the primary relay point for vagal nerve fibers to the brain. These studies are all consistent with nVNS resulting in stimulation of the vagus nerve with resultant central effects in

the brain. Other studies of neurobiology are also consistent with the role of nVNS in stimulating the vagus nerve.

nVNS has effects on a range of stress-related biological parameters. Studies using taVNS showed improved vagal activity [272,273], increased salivary alpha amylase, and decreased salivary cortisol [274]. Psychophysiology-focused studies have produced mixed outcomes. Whereas some studies noted no effect of taVNS on physiological markers of autonomic activity, such as pupil size, startle blink electromyography, and skin conductance responses [274–276], other studies noted improvements in psychophysiological indices of vagal activity with taVNS [272,273]. Our group recently studied tcVNS in physically healthy human subjects with a three-day stress paradigm, and found favorable results, indicating decreased physiological reactivity during stress and at rest for a wide range of biomarkers that could be obtained with wearable sensing devices [277,278]. We also explored computational methods to determine stimulation presence based on these continuous assessments of autonomic activity [279]. Anti-inflammatory effects of tcVNS based on serum cytokines have been noted in different healthy human studies and patients with Primary Sjögren's Syndrome [280–282].


## 8. Noninvasive Vagal Nerve Stimulation: Application to Stress-Related Psychiatric Disorders

The requirement for direct VNS to be surgically implanted has limited widespread implementation in stress-related psychiatric disorders to date due to cost and inconvenience [125,131]. These forms of VNS are also limited by the fact that true sham-controlled trials cannot be performed due to ethical reasons, which has led to questions about the true efficacy of these devices [261]. Since devices are only implanted in patients who have not responded to multiple antidepressants, the patient populations are also not necessarily representative of those typically seen in clinical psychiatry practices, which may explain why VNS, although yielding statistically significant improvements, did not lead to complete remission in all patients [283]. Additionally, treatments have not been reimbursed by Medicare or other insurance companies, which has further limited implementation [284]. Studies have shown the utility of both tcVNS and taVNS for various psychiatric disorders, including schizophrenia [285] and obsessive-compulsive disorder [286], as well as major depression [287]. Human studies also suggest that noninvasive VNS improves hyperarousal in PTSD patients with mild traumatic brain injury [288] and reduces symptoms in treatment-resistant anxiety disorders [289].

As proven by their cost and convenience, noninvasive VNS technologies have widespread applicability to patients with stress-related psychiatric disorders.

Neck-based tcVNS was recently approved by the FDA for the treatment of intractable cluster headache [264,290–292]. We have implemented this device in healthy human subjects with a history of exposure to traumatic stressful events since 2017, and have found it to be safe and feasible [277–279]. In our studies, we compared active tcVNS to a sham control in a randomized trial (Figure 2). Both were handheld devices that were applied to the left neck for stimulation with identical placement and operation (GammaCore, ElectroCore, Basking Ridge, New Jersey). nVNS or sham were applied using collar electrodes on the left side of the neck in order to permit placement while subjects were in the research-dedicated brain scanner, which had a small aperture. The treatment area on the neck was located by finding the carotid artery pulsation. An electrically conductive gel was applied on the stimulation surfaces and device is placed on the located treatment area. Active tcVNS devices produced a 5-kHz sine wave burst lasting for 1 millisecond (five sine waves, each lasting 200 microseconds), repeated one in every 40 milliseconds (25 Hz), generating 30-V peak voltage and 60-mA peak output current. The final stimulation intensity depended on the subject's verbal feedback: The researcher was instructed to increase the intensity gradually until the subject voiced discomfort, at which point the intensity was reduced slightly below that threshold. Sham devices produced a nearly direct voltage signal, whose polarity was slowly varied (0.2-Hz biphasic voltage), in contrast to the higher-frequency, alternating current used for the active nVNS (25 Hz with 5-kHz bursts). The sham device delivered a biphasic signal generating a 14-V peak voltage and 60-mA peak output current, consisting of pulses repeating every 5 s (0.2 Hz). High-frequency voltage signals (such as the active stimulus) pass

through the skin with minimal power dissipation due to the low skin-electrode impedance at kHz frequencies. In contrast, lower-frequency signals (such as the sham stimulus) are mainly attenuated at the skin-electrode interface due to the high impedance [293]. Accordingly, the active tcVNS can deliver substantial energy to the vagus nerve to facilitate stimulation, while the voltage levels appearing at the vagus would be expected to be orders of magnitude lower for the sham device and thus vagal stimulation is unlikely. Nevertheless, since the sham device does deliver relatively high voltage and current levels directly to the skin, it activates skin nociceptors, causing a similar feeling to a pinch. This sensation is necessary for blinding of the participants and is thought as a critical detail by the investigators for the valuation of the potential treatment in psychiatric populations. Both active and sham interventions lasted for two minutes. The subject, research staff, and investigators were all blind to the device category, and the key was kept in a locked office by an individual not involved in the research in two locations. The specific details are summarized as follows: The manufacturer sent the active and sham devices to an individual who was not involved in research, and the individual randomized patients to the devices prior to patient recruitment. In addition, every subject was given a different, dedicated device, hence the number of patients was equal to the number of devices. Every week when a new patient arrived, the individual not involved in research delivered a different device to the research staff for use for that subject.



**Figure 2.** Study protocol undergoing since 2017. Physiological sensing data is collected continuously throughout three study days. The protocol timeline depicts neutral and trauma scripts, HR-PET scans (first day), mental stress tasks of public speech and mental arithmetic (second and third day), stimulation with active tcVNS or sham, and blood draws (all days).

In our study with physically healthy traumatized subjects and patients with PTSD, we constructed a multisignal dataset that include physiological signals related to cardiovascular and peripheral activity. The signals included electrocardiography (ECG), respiration (RSP), seismocardiography (SCG), photoplethysmography (PPG), electrodermal activity (EDA), and blood pressure (BP). Upon beat-by-beat signal processing, we extracted parameters related to autonomic tone with a beat-by-beat resolution. These parameters included both standard and nonstandard indices of psychophysiological reactivity, such as heart rate (HR), pre-ejection period of the heart (PEP), amplitude of the peripheral photoplethysmogram (PPG), pulse arrival time (PAT), properties of respiration signal (respiration rate, RR, width, RW, prominence, RP), frequency- and time- domain heart rate variability indices including low- and high-frequency heart rate variability (LF HRV, HF HRV), Poincare-based nonlinear heart rate variability (SD1, SD2), acceleration and deceleration capacity (AC, DC), and skin conductance level and response (SCL, SCR). In our healthy cohort, PEP, PPG amplitude, skin conductance, and respiratory indices resulted in marked differences between active and sham groups, indicating a blunted sympathetic response with tcVNS [277,294]. We later used



this blunted physiological reactivity pattern to devise a machine learning based method that could indicate stimulation presence [278,279]. Brain imaging using High-Resolution Positron Emission Tomography (HR-PET) in traumatized participants without PTSD exposed to personalized traumatic scripts showed that tcVNS compared to sham stimulation blocked activations in the medial prefrontal cortex, parahippocampal gyrus, and insula, brain areas that play key roles in emotion and response to stress [295].

We also studied the effects of tcVNS on inflammatory markers in traumatized individuals with and without PTSD. We found that tcVNS paired with personalized traumatic scripts blocked stress-induced increases in proinflammatory biomarkers IL-6 and IFN- $\gamma$ , and showed a pattern of decreased anger responses to scripts [87]. Increases in IL-6 and IFN- $\gamma$  likely occur multiple times a day with minor stressors and triggers in PTSD patients, so tcVNS could result in a decrease in symptoms driven by inflammation and lead to improvements in clinical course. The reduction in subjective anger, in addition to improved mental health, also likely have beneficial health effects, for instance, in patients with comorbid PTSD and coronary artery disease (CAD), where we found not only an increase in mental stress-induced IL-6 in those with comorbid PTSD [63], but also that anger, PTSD, and other symptoms of psychological distress were associated with long-term adverse cardiovascular outcomes [296] and an increase in mental stress-induced myocardial ischemia [297,298].

Studies are ongoing with patients with PTSD, paired with assessment of the brain with High Resolution Positron Emission Tomography (HR-PET), and assessment of inflammatory and other blood biomarkers [278]. Due to low cost, increased convenience, limited side effects, feasibility for use at home or in the field for military medicine applications, and the ability to assess efficacy with true sham control comparison, tcVNS and taVNS show great promise in our opinion for the treatment of patients with stress-related psychiatric disorders and enhancement of human performance [261].

## 9. Conclusions

Current treatments for PTSD, major depression, and other stress-related psychiatric disorders, including medications and psychotherapy, have limitations and are not efficacious for all patients. Neuromodulation is an important alternative treatment, and noninvasive forms of VNS have the advantages of cost and noninvasiveness and can potentially be widely implemented for these patients. Both tcVNS and taVNS show promise for intervening at the level of the underlying neurobiology of these disorders.

PTSD is triggered by experiencing or witnessing exposure to traumatic events and leads to uncontrollable thoughts about the events. Our results from traumatized subjects without PTSD demonstrate decreased sympathetic and increased parasympathetic tone during tcVNS following acute traumatic stress, suggesting possible translation of this treatment to patients with PTSD, in the clinic or at home, as an acute treatment for these recurrent memories [277–279,299]. tcVNS has potential promise for enhancing recovery from acute traumatic stress by means of modulation of autonomic response in PTSD populations. As patients with PTSD show exaggerated responsivity to reminders of traumatic memories, the physiological changes induced by tcVNS observed in traumatized individuals without PTSD may be similarly observed in PTSD populations. Moreover, recent studies have shown that invasive VNS enhances the extinction of conditioned fear in rats [137]. Additionally, taVNS was shown to lead to improvement in vagal tone in patients with PTSD [288] and to inhibit long-term fear responses during extinction training in healthy human subjects [300]. Implanted VNS has already been approved by the FDA as a treatment for treatment resistant depression and epilepsy, but its cost and the intrusive nature of the surgery have limited its use. Noninvasive VNS technologies would be a significant addition to both facilitate further research into the circuitry of PTSD and treatment resistant depression, and would provide a new and highly acceptable treatment option for patients suffering from both severe and recurrent depression and PTSD [134,261].

**Author Contributions:** The following authors assisted with the design and execution of the research described in the article: J.D.B., N.Z.G., M.T.W., M.H.S., M.H.R., J.A.N., B.D.P., V.V., A.J.S., O.T.I. The following authors were

involved in obtaining funding for the research: J.D.B., J.A.N., B.D.P., V.V., A.J.S., O.T.I. The following authors were involved in analysis of the data in the research: J.D.B., N.Z.G., M.T.W., M.H.S., J.A.N., B.D.P., O.T.I. The following authors drafted the initial article: J.D.B., N.Z.G., M.T.W., M.H.S., O.T.I. The following authors created the figures in the article: N.Z.G. The following authors added critical revisions to the article: J.D.B., N.Z.G., M.T.W., M.H.S., M.H.R., J.A.N., B.D.P., V.V., A.J.S., J.P., M.B., O.T.I. All authors have read and agreed to the published version of the manuscript.

**Funding:** The work reviewed here was supported by the Defense Advanced Research Projects Agency (DARPA), Arlington, VA, under Cooperative Agreement N66001-16-2-4054. Shah is sponsored by the National Institutes of Health, Award K23 HL127251.

**Conflicts of Interest:** J.D.B. has research funding support from ElectroCore LLC who also donated devices used in the research reviewed here.

## References

1. Anda, R.F.; Felitti, V.J.; Walker, J.; Whitfield, C.; Bremner, J.D.; Perry, B.D.; Dube, S.R.; Giles, W.H. The enduring effects of childhood abuse and related experiences in childhood: A convergence of evidence from neurobiology and epidemiology. *Eur. Arch. Psychiatry Clin. Neurosci.* **2006**, *256*, 174–186. [[CrossRef](#)] [[PubMed](#)]
2. Kessler, R.C.; Magee, W.J. Childhood adversities and adult depression: Basic patterns of association in a US national survey. *Psychol. Med.* **1993**, *23*, 679–690. [[CrossRef](#)] [[PubMed](#)]
3. Kendler, K.S.; Thornton, L.M.; Gardner, C.O. Stressful life events and previous episodes in the etiology of major depression in women: An evaluation of the “kindling” hypothesis. *Am. J. Psychiatry* **2000**, *157*, 1243–1251. [[CrossRef](#)] [[PubMed](#)]
4. Weathers, F.W.; Bovin, M.J.; Lee, D.J.; Sloan, D.M.; Schnurr, P.P.; Kaloupek, D.G.; Keane, T.M.; Marx, B.P. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. *Psychol. Assess.* **2018**, *30*, 383–395. [[CrossRef](#)]
5. Kessler, R.C.; McGonagle, K.A.; Zhao, S.; Nelson, C.B.; Hughes, M.; Eschleman, S.; Wittchen, H.-U.; Kendler, K. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Study. *Arch. Gen. Psychiatry* **1994**, *51*, 8–19. [[CrossRef](#)]
6. Stewart, W.F.; Ricci, J.A.; Chee, E.; Hahn, S.R.; Morganstein, D. Cost of lost productive work time among US workers with depression. *J. Am. Med. Assoc.* **2003**, *289*, 3135–3144. [[CrossRef](#)]
7. Pietrzak, R.H.; Goldstein, R.B.; Southwick, S.M.; Grant, B.F. Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: Results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. *J. Anxiety Disord.* **2011**, *25*, 456–465. [[CrossRef](#)]
8. Eibner, C. *The Invisible Wounds of War: Quantifying the Societal Costs of Psychological and Cognitive Injuries*; RAND Corporation: Santa Monica, CA, USA, 2008.
9. McCauley, J.; Kern, D.E.; Kolodner, K.; Dill, L.; Schroeder, A.F.; DeChant, H.K.; Ryden, J.; Derogatis, L.R.; Bass, E.G. Clinical characteristics of women with a history of childhood abuse: Unhealed wounds. *J. Am. Med. Assoc.* **1997**, *277*, 1362–1368. [[CrossRef](#)]
10. MacMillan, H.L.; Fleming, J.E.; Trocme, N.; Boyle, M.H.; Wong, M.; Racine, Y.A.; Beardslee, W.R.; Offord, D.R. Prevalence of child physical and sexual abuse in the community: Results from the Ontario Health Supplement. *J. Am. Med. Assoc.* **1997**, *278*, 131–135. [[CrossRef](#)]
11. Kessler, R.C.; Sonnega, A.; Bromet, E.; Hughes, M.; Nelson, C.B. Posttraumatic stress disorder in the National Comorbidity Survey. *Arch. Gen. Psychiatry* **1995**, *52*, 1048–1060. [[CrossRef](#)]
12. Kessler, R.C.; Berglund, P.; Demler, O.; Jin, R.; Merikangas, K.R.; Walters, E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch. Gen. Psychiatry* **2005**, *62*, 593–602. [[CrossRef](#)] [[PubMed](#)]
13. Bremner, J.D. (Ed.) *Posttraumatic Stress Disorder: From Neurobiology to Treatment*, 1st ed.; John Wiley & Sons: Hoboken, NJ, USA, 2016.
14. Blanchard, E.B.; Buckley, T.C.; Hickling, E.J.; Taylor, A.E. Posttraumatic stress disorder and comorbid major depression: Is the correlation an illusion? *J. Anxiety Disord.* **1998**, *12*, 1–37. [[CrossRef](#)]
15. Franklin, C.L.; Zimmerman, M. Posttraumatic stress disorder and major depressive disorder: Investigating the role of overlapping symptoms in diagnostic comorbidity. *J. Nerv. Ment. Dis.* **2001**, *189*, 548–551. [[CrossRef](#)] [[PubMed](#)]

16. Flory, J.D.; Yehuda, R. Comorbidity between post-traumatic stress disorder and major depressive disorder: Alternative explanations and treatment considerations. *Dialogues Clin. Neurosci.* **2015**, *17*, 141–150.
17. Nijdam, M.J.; Gersons, B.P.R.; Olff, M. The role of major depression in neurocognitive functioning in patients with posttraumatic stress disorder. *Eur. J. Psychotraumatol.* **2013**, *4*, 19979. [[CrossRef](#)]
18. Shalev, A.Y.; Freedman, S.; Peri, T. Prospective study of post-traumatic stress disorder and depression following trauma. *Am. J. Psychiatry* **1988**, *155*, 630–637. [[CrossRef](#)]
19. Rytwinski, N.K.; Scur, M.D.; Feeny, N.C.; Youngstrom, E.A. The co-occurrence of major depressive disorder among individuals with posttraumatic stress disorder: A meta-analysis. *J. Trauma. Stress* **2013**, *26*, 299–309. [[CrossRef](#)]
20. Oquendo, M.; Brent, D.A.; Birmaher, B.; Greenhill, L.; Kolko, D.; Stanley, B.; Zelazny, J.; Burke, A.K.; Firinciogullari, S.; Ellis, S.P.; et al. Posttraumatic stress disorder comorbid with major depression: Factors mediating the association with suicidal behavior. *Am. J. Psychiatry* **2005**, *162*, 560–566. [[CrossRef](#)]
21. Ramsawh, H.J.; Fullerton, C.S.; Mash, H.B.H.; Ng, T.H.H.; Kessler, R.C.; Stein, M.B.; Ursano, R.J. Risk for suicidal behaviors associated with PTSD, depression, and their comorbidity in the U.S. Army. *J. Affect. Disord.* **2014**, *161*, 116–122. [[CrossRef](#)]
22. Ballenger, J.C.; Davidson, J.R.; Lecrubier, Y.; Nutt, D.J.; Foa, E.B.; Kessler, R.C.; McFarlane, A.C.; Shalev, A.Y. Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. *J. Clin. Psychiatry* **2000**, *61*, 60–66.
23. Foa, E.B.; Davidson, J.R.T.; Frances, A.; Culpepper, L.; Ross, R.; Ross, D. The expert consensus guideline series: Treatment of posttraumatic stress disorder. *J. Clin. Psychiatry* **1999**, *60*, 4–76.
24. Schottenbauer, M.A.; Glass, C.R.; Arnkoff, D.B.; Tendick, V.; Gray, S.H. Nonresponse and dropout rates in outcome studies on PTSD: Review and methodological considerations. *Psychiatry* **2008**, *71*, 134–168. [[CrossRef](#)] [[PubMed](#)]
25. Hembree, E.A.; Foa, E.B.; Dorfan, N.M.; Street, G.P.; Kowalski, J.; Tu, X. Do patients drop out prematurely from exposure therapy for PTSD? *J. Trauma. Stress* **2003**, *16*, 555–562. [[CrossRef](#)] [[PubMed](#)]
26. Ballenger, J.C.; Davidson, J.R.; Lecrubier, Y.; Nutt, D.J.; Marshall, R.D.; Nemeroff, C.B.; Shalev, A.Y.; Yehuda, R. Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety. *J. Clin. Psychiatry* **2004**, *65* (Suppl. 1), 55–62.
27. Davis, L.; Hamner, M.; Bremner, J.D. Pharmacotherapy for PTSD: Effects on PTSD symptoms and the brain. In *Posttraumatic Stress Disorder: From Neurobiology to Treatment*; Bremner, J.D., Ed.; John Wiley & Sons: Hoboken, NJ, USA, 2016; pp. 389–412.
28. Institute of Medicine of the National Academies. *Treatment for Posttraumatic Stress Disorder in Military and Veteran Populations: Final Assessment*; National Academies of Science, Engineering and Medicine, Health and Medicine Division: Washington, DC, USA, 2014.
29. Rush, A.J.; Trivedi, M.H.; Wisniewski, S.R.; Nierenberg, A.A.; Stewart, J.W.; Warden, D.; Niederehe, G.; Thase, M.E.; Lavori, P.W.; Lebowitz, B.D.; et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR\*D report. *Am. J. Psychiatry* **2006**, *163*, 1905–1907. [[CrossRef](#)]
30. Komegae, E.N.; Farmer, D.G.S.; Brooks, V.L.; McKinley, M.J.; McAllen, R.M.; Martelli, D. Vagal afferent activation suppresses systemic inflammation via the splanchnic anti-inflammatory pathway. *Brain Behav. Immun.* **2018**, *73*, 441–449. [[CrossRef](#)]
31. Bremner, J.D.; Charney, D.S. Neural circuits in fear and anxiety. In *Textbook of Anxiety Disorders*, 2nd ed.; Stein, D.J., Hollander, E., Rothbaum, B.O., Eds.; American Psychiatric Publishing: Arlington, VA, USA, 2010; pp. 55–71.
32. Charney, D.S.; Bremner, J.D. The neurobiology of anxiety disorders. In *Neurobiology of Mental Illness*; Charney, D.S., Nestler, E.J., Bunney, S.S., Eds.; Oxford University Press: Oxford, UK, 1999; pp. 494–517.
33. Bremner, J.D.; Pearce, B. Neurotransmitter, neurohormonal, and neuropeptid function in stress and PTSD. In *Posttraumatic Stress Disorder: From Neurobiology to Treatment*; Bremner, J.D., Ed.; John Wiley & Sons: Hoboken, NJ, USA, 2016; pp. 181–232.
34. Campanella, C.; Bremner, J.D. Neuroimaging of PTSD. In *Posttraumatic Stress Disorder: From Neurobiology to Treatment*; Bremner, J.D., Ed.; John Wiley & Sons: Hoboken, NJ, USA, 2016; pp. 291–320.
35. Yehuda, R. Post-traumatic stress disorder. *N. Engl. J. Med.* **2002**, *346*, 108–114. [[CrossRef](#)]
36. Vermetten, E. Epilogue: Neuroendocrinology of PTSD. *Prog. Brain Res.* **2008**, *167*, 311–313. [[CrossRef](#)]

37. De Kloet, C.S.; Vermetten, E.; Geuze, E.; Kavelaars, A.; Heijnen, C.J.; Westenberg, H.G. Assessment of HPA-axis function in posttraumatic stress disorder: Pharmacological and non-pharmacological challenge tests, a review. *J. Psychiatr. Res.* **2006**, *40*, 550–567. [[CrossRef](#)]
38. Van Zuiden, M.; Kavelaars, A.; Geuze, E.; Olf, M.; Heijnen, C.J. Predicting PTSD: Pre-existing vulnerabilities in glucocorticoid-signaling and implications for preventive interventions. *Brain Behav. Immun.* **2013**, *30*, 12–21. [[CrossRef](#)]
39. Yehuda, R.; Golier, J.A.; Yang, R.-K.; Tischler, L. Enhanced sensitivity to glucocorticoids in peripheral mononuclear leukocytes in posttraumatic stress disorder. *Biol. Psychiatry* **2004**, *55*, 1110–1116. [[CrossRef](#)] [[PubMed](#)]
40. Young, E.A.; Haskett, R.F.; Murphy-Weinberg, V.; Watson, S.J.; Akil, H. Loss of glucocorticoid fast feedback in depression. *Arch. Gen. Psychiatry* **1991**, *48*, 693–699. [[CrossRef](#)] [[PubMed](#)]
41. Yehuda, R.; Teicher, M.H.; Trestman, R.L.; Levengood, R.A.; Siever, L.J. Cortisol regulation in posttraumatic stress disorder and major depression: A chronobiological analysis. *Biol. Psychiatry* **1996**, *40*, 79–88. [[CrossRef](#)]
42. Carroll, B.J.; Curtis, G.C.; Davies, B.M.; Mendels, J.; Sugarman, A.A. Urinary free cortisol excretion in depression. *Psychol. Med.* **1976**, *6*, 43–50. [[CrossRef](#)]
43. Hosoi, T.; Okuma, Y.; Nomura, Y. Electrical stimulation of afferent vagus nerve induces IL-1 $\beta$  expression in the brain and activates HPA axis. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **2000**, *279*, R141–R147. [[CrossRef](#)]
44. Watkins, L.R.; Maier, S.F.; Goehler, L.E. Cytokine-to-brain communication: A review and analysis of alternative mechanisms. *Life Sci.* **1995**, *57*, 1011–1026. [[CrossRef](#)]
45. Thiruvikraman, K.V.; Zejnelovic, F.; Bonsall, R.W.; Owens, M.J. Neuroendocrine homeostasis after vagus nerve stimulation in rats. *Psychoneuroendocrinology* **2013**, *38*, 1067–1077. [[CrossRef](#)]
46. Agorastos, A.; Boel, J.A.; Heppner, P.S.; Hager, T.; Moeller-Bertram, T.; Haji, U.; Motazed, A.; Yanagi, M.A.; Baker, D.G.; Stiedl, O. Diminished vagal activity and blunted diurnal variation of heart rate dynamics in posttraumatic stress disorder. *Stress* **2013**, *16*, 300–310. [[CrossRef](#)]
47. Delgado, P.L.; Moreno, F.A. Role of norepinephrine in depression. *J. Clin. Psychiatry* **2000**, *61*, S5–S12.
48. Golden, R.N.; Markey, S.P.; Risby, E.D.; Rudorfer, M.V.; Cowdry, R.W.; Potter, W.Z. Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output. *Arch. Gen. Psychiatry* **1988**, *45*, 150–154. [[CrossRef](#)]
49. Lake, C.R.; Pickar, D.; Ziegler, M.G.; Lipper, S.; Slater, S.; Murphy, D.L. High plasma NE levels in patients with major affective disorder. *Am. J. Psychiatry* **1982**, *139*, 1315–1318. [[PubMed](#)]
50. Veith, R.C.; Lewis, L.; Linares, O.A. Sympathetic nervous system activity in major depression: Basal and desipramine-induced alterations in plasma norepinephrine kinetics. *Arch. Gen. Psychiatry* **1994**, *51*, 411–422. [[CrossRef](#)] [[PubMed](#)]
51. Bremner, J.D.; Krystal, J.H.; Southwick, S.M.; Charney, D.S. Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. *Synapse* **1996**, *23*, 39–51. [[CrossRef](#)]
52. Blanchard, E.B.; Kolb, L.C.; Prins, A.; Gates, S.; McCoy, G.C. Changes in plasma norepinephrine to combat-related stimuli among Vietnam veterans with posttraumatic stress disorder. *J. Nerv. Ment. Dis.* **1991**, *179*, 371–373. [[CrossRef](#)]
53. Geraciotti, T.D.J.; Baker, D.G.; Ekhtor, N.N.; West, S.A.; Hill, K.K.; Bruce, A.B.; Schmidt, D.; Rounds-Kugler, B.; Yehuda, R.; Keck, P.E.J.; et al. CSF norepinephrine concentrations in posttraumatic stress disorder. *Am. J. Psychiatry* **2001**, *158*, 1227–1230. [[CrossRef](#)]
54. Mason, J.W.; Giller, E.L.; Kosten, T.R. Elevation of urinary norepinephrine/cortisol ratio in posttraumatic stress disorder. *J. Nerv. Ment. Dis.* **1988**, *176*, 498–502. [[CrossRef](#)]
55. Zoladz, P.R.; Diamond, D.M. Current status on behavioral and biological markers of PTSD: A search for clarity in a conflicting literature. *Neurosci. Biobehav. Rev.* **2013**, *37*, 860–895. [[CrossRef](#)]
56. Bremner, J.D.; Krystal, J.H.; Southwick, S.M.; Charney, D.S. Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. *Synapse* **1996**, *23*, 28–38. [[CrossRef](#)]
57. Southwick, S.M.; Krystal, J.H.; Bremner, J.D.; Morgan, C.A.; Nicolaou, A.; Nagy, L.M.; Johnson, D.R.; Heninger, G.R.; Charney, D.S. Noradrenergic and serotonergic function in posttraumatic stress disorder. *Arch. Gen. Psychiatry* **1997**, *54*, 749–758. [[CrossRef](#)]
58. Miller, A.H.; Raison, C.L. The role of inflammation in depression: From evolutionary imperative to modern treatment target. *Nat. Rev. Immunol.* **2016**, *16*, 22–34. [[CrossRef](#)]



59. Pace, T.W.W.; Heim, C.M. A short review on the psychoneuroimmunology of posttraumatic stress disorder: From risk factors to medical comorbidities. *Brain Behav. Immun.* **2011**, *25*, 6–13. [[CrossRef](#)] [[PubMed](#)]
60. Marsland, A.L.; Walsh, C.; Lockwood, K.; John-Henderson, N.A. The effects of acute psychological stress on circulating and stimulated inflammatory markers: A systematic review and meta-analysis. *Brain Behav. Immun.* **2017**, *64*, 208–219. [[CrossRef](#)] [[PubMed](#)]
61. Steptoe, A.; Hamer, M.; Chida, Y. The effects of acute psychological stress on circulating inflammatory factors in humans: A review and meta-analysis. *Brain Behav. Immun.* **2007**, *21*, 901–912. [[CrossRef](#)] [[PubMed](#)]
62. Sugama, S.; Conti, B. Interleukin-18 and stress. *Brain Res. Rev.* **2008**, *58*, 85–95. [[CrossRef](#)]
63. Lima, B.B.; Hammadah, M.; Wilmot, K.; Pearce, B.D.; Shah, A.; Levantsevych, O.; Kaseer, B.; Obideen, M.; Gafeer, M.M.; Kim, J.H.; et al. Posttraumatic Stress Disorder is associated with enhanced interleukin-6 response to mental stress in subjects with a recent myocardial infarction. *Brain Behav. Immun.* **2019**, *75*, 26–33. [[CrossRef](#)]
64. Pace, T.W.W.; Mletzko, T.C.; Alagbe, O.; Musselman, D.L.; Nemeroff, C.B.; Miller, A.H.; Heim, C.M. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. *Am. J. Psychiatry* **2006**, *163*, 1630–1633. [[CrossRef](#)]
65. Miller, A.H.; Maletic, V.; Raison, C.L. Inflammation and its discontents: The role of cytokines in the pathophysiology of depression. *Biol. Psychiatry* **2009**, *65*, 732–741. [[CrossRef](#)]
66. Bierhaus, A.; Wolf, J.; Andrassy, M.; Rohleder, N.; Humpert, P.M.; Petrov, D.; Ferstl, R.; von Eynatten, M.; Wendt, T.; Rudofsky, G.; et al. A mechanism converting psychosocial stress into mononuclear cell activation. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 1920–1925. [[CrossRef](#)]
67. Raison, C.L.; Miller, A.H. The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D). *Mol. Psychiatry* **2013**, *18*, 15–37. [[CrossRef](#)]
68. Passos, C.I.; Vasconcelos-Moreno, M.P.; Costa, L.G.; Kunz, M.; Brietzke, E.; Quevedo, J.; Salum, G.; Magalhães, P.V.; Kapczinski, F.; Kauer-Sant’Anna, M. Inflammatory markers in post-traumatic stress disorder: A systematic review, meta-analysis, and meta-regression. *Lancet Psychiatry* **2015**, *2*, 1002–1012. [[CrossRef](#)]
69. Felger, J.C.; Li, L.; Marvar, P.J.; Woolwine, B.J.; Harrison, D.G.; Raison, C.L.; Miller, A.H. Tyrosine metabolism during interferon- $\alpha$  administration: Association with fatigue and CSF dopamine concentrations. *Brain Behav. Immun.* **2013**, *31*, 153–160. [[CrossRef](#)] [[PubMed](#)]
70. Raison, C.L.; Kelley, K.W.; Lawson, M.A.; Woolwine, B.J.; Vogt, G.; Spivey, J.R.; Saito, K.; Miller, A.H. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN- $\alpha$ : Relationship to CNS immune responses and depression. *Mol. Psychiatry* **2010**, *15*, 393–403. [[CrossRef](#)] [[PubMed](#)]
71. Delgado, P.L.; Price, L.H.; Miller, A.H.; Salomon, R.M.; Aghajanian, G.K.; Heninger, G.R.; Charney, D.S. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. *Arch. Gen. Psychiatry* **1994**, *51*, 865–874. [[CrossRef](#)] [[PubMed](#)]
72. Myint, A.M. Kynurenines: From the perspective of major psychiatric disorders. *FEBS J.* **2012**, *279*, 1375–1385. [[CrossRef](#)]
73. Duman, R.S.; Malberg, J.E.; Nakagawa, S. Regulation of adult neurogenesis by psychotropic drugs and stress. *J. Pharmacol. Exp. Ther.* **2001**, *299*, 401–407.
74. Duman, R.S. Depression: A case of neuronal life and death? *Biol. Psychiatry* **2004**, *56*, 140–145. [[CrossRef](#)]
75. Nibuya, M.; Morinobu, S.; Duman, R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. *J. Neurosci.* **1995**, *15*, 7539–7547. [[CrossRef](#)]
76. Santarelli, L.; Saxe, M.; Gross, C.; Surget, A.; Battaglia, F.; Dulawa, S.; Weisstaub, N.; Lee, J.; Duman, R.; Arancio, O.; et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. *Science* **2003**, *301*, 805–809. [[CrossRef](#)]
77. Nizri, E.; Brenner, T. Modulation of inflammatory pathways by the immune cholinergic system. *Amino Acids* **2013**, *45*, 73–85. [[CrossRef](#)]
78. Griffin, G.D.; Charron, D.; Al-Daccak, R. Post-traumatic stress disorder: Revisiting adrenergics, glucocorticoids, immune system effects and homeostasis. *Clin. Transl. Immunol.* **2014**, *3*, e27. [[CrossRef](#)]
79. Zhou, J.; Nagarkatti, P.; Zhong, Y.; Ginsberg, J.P.; Singh, N.P.; Zhang, J.; Nagarkatti, M. Dysregulation in microRNA expression is associated with alterations in immune functions in combat veterans with post-traumatic stress disorder. *PLoS ONE* **2014**, *9*, e94075. [[CrossRef](#)] [[PubMed](#)]



80. Bremner, D.; Vermetten, E.; Kelley, M.E. Cortisol, dehydroepiandrosterone, and estradiol measured over 24 hours in women with childhood sexual abuse-related posttraumatic stress disorder. *J. Nerv. Ment. Dis.* **2007**, *195*, 919–927. [[CrossRef](#)] [[PubMed](#)]
81. Wilson, S.N.; van der Kolk, B.; Burbridge, J.; Fislser, R.; Kradin, R. Phenotype of blood lymphocytes in PTSD suggests chronic immune activation. *Psychosomatics* **1999**, *40*, 222–225. [[CrossRef](#)]
82. Altemus, M.; Cloitre, M.; Dhabhar, F.S. Enhanced cellular immune response in women with PTSD related to childhood abuse. *Am. J. Psychiatry* **2003**, *160*, 1705–1707. [[CrossRef](#)] [[PubMed](#)]
83. Barth, H.; Berg, P.A.; Klein, R. Method for the in vitro determination of an individual disposition towards Th1- or Th2-reactivity by the application of appropriate stimulatory antigens. *Clin. Exp. Immunol.* **2003**, *134*, 78–85. [[CrossRef](#)]
84. Woods, A.B.; Page, G.G.; O'Campo, P.; Pugh, L.C.; Ford, D.; Campbell, J.C. The mediation effect of posttraumatic stress disorder symptoms on the relationship of intimate partner violence and IFN-gamma levels. *Am. J. Community Psychol.* **2005**, *36*, 159–175. [[CrossRef](#)]
85. Lindqvist, D.; Wolkowitz, O.M.; Mellon, S.; Yehuda, R.; Flory, J.D.; Henn-Haase, C.; Bierer, L.M.; Abu-Amara, D.; Coy, M.; Neylan, T.C.; et al. Proinflammatory milieu in combat-related PTSD is independent of depression and early life stress. *Brain Behav. Immun.* **2014**, *42*, 81–88. [[CrossRef](#)] [[PubMed](#)]
86. Rosas-Ballina, M.; Olofsson, P.S.; Ochani, M.; Valdés-Ferrer, S.I.; Levine, Y.A.; Reardon, C.; Tusche, M.W.; Pavlov, V.A.; Andersson, U.; Chavan, S.; et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. *Science* **2011**, *334*, 98–101. [[CrossRef](#)]
87. Bremner, J.D.; Gurel, N.Z.; Jiao, Y.; Wittbrodt, M.T.; Levantsevych, O.M.; Huang, M.; Jung, H.; Shandhi, M.H.; Beckwith, J.; Herring, I.; et al. Transcutaneous vagal nerve stimulation blocks stress-induced activation of interleukin-6 and interferon- $\gamma$  in posttraumatic stress disorder: A double-blind, randomized, sham-controlled trial. *Brain Behav. Immun. Health* **2020**, in press.
88. Huston, J.M.; Gallowitsch-Puerta, M.; Ochani, M.; Ochani, K.; Yuan, R.; Rosas-Ballina, M.; Ashok, M.; Goldstein, R.S.; Chavan, S.; Pavlov, V.A. Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. *Crit. Care Med.* **2007**, *35*, 2762–2768. [[CrossRef](#)]
89. Wang, X.-W.; Karki, A.; Du, D.-Y.; Zhao, X.-J.; Xiang, X.-Y.; Lu, Z.-Q. Plasma levels of high mobility group box 1 increase in patients with posttraumatic stress disorder after severe blunt chest trauma: A prospective cohort study. *J. Surg. Res.* **2015**, *193*, 308–315. [[CrossRef](#)] [[PubMed](#)]
90. Gray, S.L.; Cline, D.L. PACAP: Regulator of the stress response. In *Stress: Physiology, Biochemistry, and Pathology*; Elsevier: Amsterdam, The Netherlands, 2019; pp. 279–291.
91. Ressler, K.J.; Mercer, K.B.; Bradley, B.; Jovanovic, T.; Mahan, A.; Kerley, K.; Norrholm, S.D.; Kilaru, V.; Smith, A.K.; Myers, A.J.; et al. Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. *Nature* **2011**, *470*, 492–497. [[CrossRef](#)] [[PubMed](#)]
92. Jovanovic, T.; Norrholm, S.D.; Davis, J.; Mercer, K.B.; Almlil, L.; Nelson, A.; Cross, D.; Smith, A.; Ressler, K.J.; Bradley, B. PAC1 receptor (ADCYAP1R1) genotype is associated with dark-enhanced startle in children. *Mol. Psychiatry* **2013**, *18*, 742–743. [[CrossRef](#)] [[PubMed](#)]
93. Kamkwalala, A.; Norrholm, S.D.; Poole, J.M.; Brown, A.; Donley, S.; Duncan, E.; Bradley, B.; Ressler, K.J.; Jovanovic, T. Dark-enhanced startle responses and heart rate variability in a traumatized civilian sample: Putative sex-specific correlates of posttraumatic stress disorder. *Psychosom. Med.* **2012**, *74*, 153. [[CrossRef](#)] [[PubMed](#)]
94. Morgan, C.A.; Grillon, C.; Lubin, H.; Southwick, S.M. Startle reflex abnormalities in women with sexual assault-related posttraumatic stress disorder. *Am. J. Psychiatry* **1997**, *154*, 1076–1080. [[PubMed](#)]
95. Jovanovic, T.; Norrholm, S.D.; Blanding, N.Q.; Phifer, J.E.; Weiss, T.; Davis, M.; Duncan, E.; Bradley, B.; Ressler, K.J. Fear potentiation is associated with hypothalamic–pituitary–adrenal axis function in PTSD. *Psychoneuroendocrinology* **2010**, *35*, 846–857. [[CrossRef](#)] [[PubMed](#)]
96. Davis, M.; Walker, D.L.; Lee, Y.S. Roles of the amygdala and bed nucleus of the stria terminalis in fear and anxiety measured with the acoustic startle reflex: Possible relevance to PTSD. *Ann. N. Y. Acad. Sci.* **1997**, *821*, 305–331. [[CrossRef](#)]
97. Starr, E.R.; Margiotta, J.F. PACAP modulates distinct neuronal components to induce cell-specific plasticity at central and autonomic synapses. In *Pituitary Adenylate Cyclase Activating Polypeptide—PACAP*; Springer: Berlin/Heidelberg, Germany, 2016; pp. 83–107.

98. Cagampang, F.R.A.; Piggins, H.D.; Sheward, W.J.; Harmar, A.J.; Coen, C.W. Circadian changes in PACAP type 1 (PAC1) receptor mRNA in the rat suprachiasmatic and supraoptic nuclei. *Brain Res.* **1998**, *813*, 218–222. [[CrossRef](#)]
99. Piggins, H.D.; Stamp, J.A.; Burns, J.; Rusak, B.; Semba, K. Distribution of pituitary adenylate cyclase activating polypeptide (PACAP) immunoreactivity in the hypothalamus and extended amygdala of the rat. *J. Comp. Neurol.* **1996**, *376*, 278–294. [[CrossRef](#)]
100. Adair, D.; Truong, D.; Esmailpour, Z.; Gebodh, N.; Borges, H.; Ho, L.; Bremner, J.D.; Badran, B.W.; Napadow, V.; Clark, V.P.; et al. Electrical stimulation of cranial nerves in cognition and disease. *Brain Stimul.* **2020**, *13*, 713–720. [[CrossRef](#)]
101. Krames, E.; Peckham, P.H.; Rezai, A. *Neuromodulation: Comprehensive Textbook of Principles, Technologies, and Therapies*, 2nd ed.; Academic Press: London, UK, 2018.
102. Brunoni, A.R.; Moffa, A.H.; Sampaio-Junior, B.; Borrión, L.; Moreno, M.L.; Fernandes, R.A.; Veronezi, B.P.; Nogueira, B.S.; Aparicio, L.V.M.; Razza, L.B.; et al. Trial of electrical Direct-Current Therapy versus escitalopram for depression. *N. Engl. J. Med.* **2017**, *376*, 2523–2533. [[CrossRef](#)] [[PubMed](#)]
103. Bikson, M.; Unal, G.; Brunoni, A.; Loo, C. What psychiatrists need to know about transcranial direct current stimulation. *Psychiatr. Times* **2017**, *34*, 1–3.
104. Bikson, M.; Grossman, P.; Thomas, C.; Zannou, A.L.; Jiang, J.; Adnan, T.; Mourdoukoutas, A.P.; Kronberg, G.; Truong, D.; Boggio, P.; et al. Safety of transcranial Direct Current Stimulation: Evidence based update 2016. *Brain Stimul.* **2016**, *9*, 641–661. [[CrossRef](#)] [[PubMed](#)]
105. Bikson, M.; Bulow, P.; Stiller, J.W.; Datta, A.; Battaglia, F.; Karnup, S.V.; Postolache, T.T. Transcranial direct current stimulation for major depression: A general system for quantifying transcranial electrotherapy dosage. *Curr. Treat. Options Neurol.* **2008**, *10*, 377–385. [[CrossRef](#)] [[PubMed](#)]
106. Woods, A.J.; Antal, A.; Bikson, M.; Boggio, P.S.; Brunoni, A.R.; Celnik, P.; Cohen, L.G.; Fregni, F.; Herrmann, C.S.; Kappenman, E.S.; et al. A technical guide to tDCS, and related non-invasive brain stimulation tools. *Clin. Neurophysiol.* **2016**, *127*, 1031–1048. [[CrossRef](#)]
107. McCann, U.D.; Kimbrell, T.A.; Morgan, C.M.; Anderson, T.; Geraci, M.; Benson, B.E.; Wassermann, E.M.; Willis, M.W.; Post, R.M. Repetitive transcranial magnetic stimulation for posttraumatic stress disorder. *Arch. Gen. Psychiatry* **1998**, *55*, 276–279. [[CrossRef](#)]
108. Tortella, G.; Casati, R.; Aparicio, L.V.M.; Mantovani, A.; Senço, N.; D’Urso, G.; Brunelin, J.; Guarienti, F.; Lorencini Selingardi, P.M.; Muszkat, D.; et al. Transcranial direct current stimulation in psychiatric disorders. *World J. Psychiatry* **2015**, *5*, 88–102. [[CrossRef](#)]
109. Schachter, S.C.; Saper, C.B. Vagus nerve stimulation. *Epilepsia* **1998**, *39*, 677–686. [[CrossRef](#)]
110. Lisanby, S.H. Electroconvulsive therapy for depression. *N. Engl. J. Med.* **2007**, *357*, 1939–1945. [[CrossRef](#)]
111. Tess, A.V.; Smetana, G.W. Medical evaluation of patients undergoing electroconvulsive therapy. *N. Engl. J. Med.* **2009**, *360*, 1437–1444. [[CrossRef](#)]
112. Haq, A.U.; Sitzmann, A.F.; Goldman, M.L.; Maixner, D.F.; Mickey, B.J. Response of depression to electroconvulsive therapy: A meta-analysis of clinical predictors. *J. Clin. Psychiatry* **2015**, *76*, 1374–1384. [[CrossRef](#)] [[PubMed](#)]
113. Maier, H.; Helm, S.; Toto, S.; Moschny, N.; Sperling, W.; Hillemacher, T.; Kahl, K.G.; Jakubowski, E.; Bleich, S.; Frieling, H.; et al. S100B, homocysteine, vitamin B12, folic acid, and procalcitonin serum levels in remitters to electroconvulsive therapy: A pilot study. *Dis. Markers* **2018**. [[CrossRef](#)] [[PubMed](#)]
114. Scott, A.I.F.; Dougall, N.; Ross, M.; O’Carroll, R.E.; Riddle, W.; Ebmeier, K.P.; Goodwin, G.M. Short-term effects of electroconvulsive treatment on the uptake of [<sup>125</sup>I] eximetazine into brain in major depression shown with single photon emission tomography. *J. Affect. Disord.* **1994**, *30*, 27–34. [[CrossRef](#)]
115. Ben-Menachem, E.; Hellström, K.; Waldton, C.; Augustinsson, L.E. Evaluation of refractory epilepsy treated with vagus nerve stimulation for up to 5 years. *Neurology* **1999**, *52*, 1265–1267. [[CrossRef](#)] [[PubMed](#)]
116. Ben-Menachem, E.; Manon-Espaillet, R.; Ristanovic, R.; Wilder, B.J.; Stefan, H.; Mirza, W.; Tarver, W.B.; Wernicke, J.F. Vagus nerve stimulation for treatment of partial seizures: 1. A controlled study of effect on seizures. *Epilepsia* **1994**, *35*, 616–626. [[CrossRef](#)] [[PubMed](#)]
117. George, R.; Salinsky, M.; Kuzniecky, R.; Rosenfeld, W.; Bergen, D.; Tarver, W.B.; Wernicke, J.F. Vagus nerve stimulation for treatment of partial seizures: 3. Long-term follow-up on the first 67 patients exiting a controlled study. *Epilepsia* **1994**, *35*, 637–643. [[CrossRef](#)]

118. Handforth, A.; DeGiorgio, C.M.; Schachter, S.C.; Uthman, B.M.; Naritoku, D.K.; Tecoma, E.S.; Henry, T.R.; Collins, S.D.; Vaughn, B.V.; Gilmartin, R.C.; et al. Vagus nerve stimulation therapy for partial-onset seizures: A randomized active-control trial. *Neurology* **1998**, *51*, 48–55. [[CrossRef](#)]
119. Salinsky, M.C.; Uthman, B.M.; Ristanovic, R.K.; Wernicke, J.F.; Tarver, W.B. Vagus nerve stimulation for the treatment of medically intractable seizures. Results of a 1-year open-extension trial. *Arch. Neurol.* **1999**, *53*, 1176–1180. [[CrossRef](#)]
120. The Vagus Nerve Stimulation Study Group. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. *Neurology* **1995**, *45*, 224–230. [[CrossRef](#)]
121. Berry, S.M.; Broglio, K.; Bunker, M.; Jayewardene, A.; Olin, B.; Rush, A.J. A patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression. *Med. Devices* **2013**, *6*, 17–35.
122. Dell-Osso, B.; Oldani, L.; Palazzo, M.C.; Balossi, I.; Ciabatti, M.; Altamura, A.C. Vagus nerve stimulation in treatment-resistant depression: Acute and follow-up results of an Italian case series. *J. ECT* **2013**, *29*, 41–44.
123. George, M.S.; Rush, A.J.; Marangell, L.B.; Sackeim, H.A.; Brannan, S.K.; Davis, S.M.; Howland, R.; Kling, M.A.; Moreno, F.; Rittberg, B.; et al. A one-year comparison of Vagus Nerve Stimulation with treatment as usual for treatment-resistant depression. *Biol. Psychiatry* **2005**, *58*, 364–373. [[CrossRef](#)]
124. George, M.S.; Rush, A.J.; Sackeim, H.A.; Marangell, L. Vagus Nerve Stimulation (VNS): Utility in neuropsychiatric disorders. *Int. J. Neuropsychopharmacol.* **2003**, *6*, 73–83. [[CrossRef](#)] [[PubMed](#)]
125. Marangell, L.B.; Rush, A.J.; George, M.S.; Sackeim, H.A.; Johnson, C.R.; Husain, M.M.; Nahas, Z.; Lisanby, S.H. Vagus Nerve Stimulation (VNS) for major depressive episodes: Longer-term outcome. *Biol. Psychiatry* **2002**, *51*, 280–287. [[CrossRef](#)]
126. Rush, A.J.; George, M.S.; Sackeim, H.A.; Marangell, L.B.; Husain, M.; Giller, C.; Nahas, Z.; Haines, S.; Simson, R.K.; Goodman, R.; et al. Vagus Nerve Stimulation (VNS) for treatment-resistant depression: A multicenter study. *Biol. Psychiatry* **2000**, *47*, 276–286. [[CrossRef](#)]
127. Rush, A.J.; Marangell, L.B.; Sackeim, H.A.; George, M.S.; Brannan, S.K.; Davis, S.M.; Howland, R.; Kling, M.A.; Rittberg, B.R.; Burke, W.J.; et al. Vagus Nerve Stimulation for treatment-resistant depression: A randomized, controlled acute phase trial. *Biol. Psychiatry* **2005**, *58*, 347–354. [[CrossRef](#)]
128. Rush, A.J.; Sackeim, H.A.; Marangell, L.B.; George, M.S.; Brannan, S.K.; Davis, S.M.; Lavori, P.; Howland, R.; Kling, M.A.; Rittberg, B.; et al. Effects of 12 Months of Vagus Nerve Stimulation in treatment-resistant depression: A naturalistic study. *Biol. Psychiatry* **2005**, *58*, 355–363. [[CrossRef](#)] [[PubMed](#)]
129. Sackeim, H.A.; Brannan, S.K.; Rush, A.J.; George, M.S.; Marangell, L.B.; Allen, J. Durability of antidepressant response to vagus nerve stimulation (VNS). *Int. J. Neuropsychopharmacol.* **2007**, *10*, 817–826. [[CrossRef](#)]
130. Sackeim, H.A.; Keilp, J.G.; Rush, A.J.; George, M.S.; Marangell, L.B.; Dormer, J.S.; Burt, T.; Lisanby, S.H.; Husain, M.; Collum, M.; et al. The effects of vagus nerve stimulation on cognitive performance in patients with treatment-resistant depression. *Neuropsychiatry Neuropsychol. Behav. Neurol.* **2001**, *14*, 53–62.
131. Sackeim, H.A.; Rush, A.J.; George, M.S.; Marangell, L.B.; Husain, M.M.; Nahas, Z.; Johnson, C.R.; Seidman, S.; Giller, C.; Haines, S.; et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: Efficacy, side effects, and predictors of outcome. *Neuropsychopharmacology* **2001**, *25*, 713–728. [[CrossRef](#)]
132. Johnson, R.L.; Wilson, C.G. A review of vagus nerve stimulation as a therapeutic intervention. *J. Inflamm. Res.* **2018**, *11*, 203–211. [[CrossRef](#)] [[PubMed](#)]
133. George, M.S.; Sackeim, H.A.; Rush, A.J.; Marangell, L.B.; Nahas, Z.; Husain, M.M.; Lisanby, S.H.; Burt, T.; Goldman, J.; Ballenger, J.C. Vagus Nerve Stimulation: A new tool for brain research and therapy. *Biol. Psychiatry* **2000**, *47*, 287–295. [[CrossRef](#)]
134. Aaronson, S.T.; Sears, P.; Ruvuna, F.; Bunker, M.; Conway, C.R.; Dougherty, D.D.; Reimherr, F.W.; Schwartz, T.L.; Zajecka, J.M. A five-year observational study of patients with treatment-resistant depression treated with VNS therapy or treatment-as-usual: Comparison of response, remission, and suicidality. *Am. J. Psychiatry* **2017**, *174*, 640–648. [[CrossRef](#)] [[PubMed](#)]
135. Terry, R.S. Vagus Nerve Stimulation for Epilepsy. *Medicine* **2014**. [[CrossRef](#)]
136. Noble, I.J.; Gonzalez, I.J.; Meruva, V.B.; Callahan, K.A.; Belfort, B.D.; Ramanathan, K.R.; Meyers, E.; Kilgard, M.P.; Rennaker, R.L.; McIntyre, C.K. Effects of vagus nerve stimulation on extinction of conditioned fear and post-traumatic stress disorder symptoms in rats. *Transl. Psychiatry* **2017**, *7*, 1–8. [[CrossRef](#)] [[PubMed](#)]

137. Pena, D.F.; Childs, J.E.; Willett, S.; Vital, A.; McIntyre, C.K.; Kroener, S. Vagus nerve stimulation enhances extinction of conditioned fear and modulates plasticity in the pathway from the ventromedial prefrontal cortex to the amygdala. *Front. Behav. Neurosci.* **2014**, *8*, 1–8. [[CrossRef](#)]
138. Schomer, A.C.; Nearing, B.D.; Schachter, S.C.; Verrier, R.L. Vagus nerve stimulation reduces cardiac electrical instability assessed by quantitative T-wave alternans analysis in patients with drug-resistant focal epilepsy. *Epilepsia* **2014**, *55*, 1996–2002. [[CrossRef](#)] [[PubMed](#)]
139. Groves, D.A.; Brown, V.J. Vagal nerve stimulation: A review of its applications and potential mechanisms that mediate its clinical effects. *Neurosci. Biobehav. Rev.* **2005**, *29*, 493–500. [[CrossRef](#)]
140. Hays, S.A.; Rennaker, R.L.; Kilgard, M.P. Targeting plasticity with vagus nerve stimulation to treat neurological disease. *Prog. Brain Res.* **2013**, *207*, 275–299.
141. Polak, T.; Markulin, F.; Ehlis, A.-C.; Langer, J.B.M.; Ringel, T.M.; Fallgatter, A.J. Far field potentials from brain stem after transcutaneous vagus nerve stimulation: Optimization of stimulation and recording parameters. *J. Neural Transm.* **2009**, *116*, 1237–1242. [[CrossRef](#)]
142. Player, M.J.; Taylor, J.L.; Weickert, C.S.; Alonzo, A.; Sachdev, P.S.; Martin, D.; Mitchell, P.B.; Loo, C.K. Increase in PAS-induced neuroplasticity after a treatment course of transcranial direct current stimulation for depression. *J. Affect. Disord.* **2014**, *167*, 140–147. [[CrossRef](#)] [[PubMed](#)]
143. Zhang, Y.; Popovic, Z.B.; Bibevski, S.; Fakhry, I.; Sica, D.A.; Van Wagoner, D.R.; Mazgalev, T.N. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. *Circ. Heart Fail.* **2009**, *2*, 692–699. [[CrossRef](#)] [[PubMed](#)]
144. Peña, D.F.; Engineer, N.D.; McIntyre, C.K. Rapid remission of conditioned fear expression with extinction training paired with vagus nerve stimulation. *Biol. Psychiatry* **2013**, *73*, 1071–1077. [[CrossRef](#)] [[PubMed](#)]
145. Souza, R.R.; Robertson, N.M.; Pruitt, D.T.; Gonzales, P.A.; Hays, S.A.; Rennaker, R.L.; Kilgard, M.P.; McIntyre, C.K. Vagus nerve stimulation reverses the extinction impairments in a model of PTSD with prolonged and repeated trauma. *Stress* **2019**, *22*, 509–520. [[CrossRef](#)] [[PubMed](#)]
146. Schacter, S.C. Vagus nerve stimulation: Mood and cognitive effects. *Epilepsy Behav.* **2004**, *5*, S56–S59. [[CrossRef](#)] [[PubMed](#)]
147. McIntire, L.; McKinley, A.; Goodyear, C. Peripheral nerve stimulation to augment human analyst performance. *IEEE* **2019**. [[CrossRef](#)]
148. Clark, K.B.; Krahl, S.E.; Smith, D.C.; Jensen, R.A. Post-training unilateral vagal stimulation enhances retention performance in the rat. *Neurobiol. Learn. Mem.* **1995**, *63*, 213–216. [[CrossRef](#)]
149. Clark, K.B.; Naritoku, D.K.; Smith, D.C.; Browning, R.A.; Jensen, R.A. Enhanced recognition memory following vagus nerve stimulation in human subjects. *Nat. Neurosci.* **1999**, *2*, 94–98. [[CrossRef](#)]
150. Clark, K.B.; Smith, D.C.; Hassert, D.L.; Browning, R.A.; Naritoku, D.K.; Jensen, R.A. Posttraining electrical stimulation of vagal afferents with concomitant vagal efferent inactivation enhances memory storage processes in the rat. *Neurobiol. Learn. Mem.* **1998**, *70*, 364–373. [[CrossRef](#)]
151. Flood, J.F.; Smith, G.E.; Morley, J.E. Modulation of memory processing by cholecystokinin: Dependence on the vagus nerve. *Science* **1987**, *236*, 832–834. [[CrossRef](#)]
152. Ghacibeh, G.A.; Shenker, J.I.; Shenal, B.; Uthman, B.M.; Heilman, K.M. The influence of vagus nerve stimulation on memory. *Cogn. Behav. Neurol.* **2006**, *19*, 119–122. [[CrossRef](#)] [[PubMed](#)]
153. Ghacibeh, G.A.; Shenker, J.I.; Shenal, B.; Uthman, B.M.; Heilman, K.M. Effect of vagus nerve stimulation on creativity and cognitive flexibility. *Epilepsy Behav.* **2006**, *8*, 720–725. [[CrossRef](#)] [[PubMed](#)]
154. Jacobs, H.I.L.; Riphagen, J.M.; Razat, C.M.; Wiese, S.; Sack, A.T. Transcutaneous vagus nerve stimulation boosts associative memory in older individuals. *Neurobiol. Aging* **2015**, *36*, 1860–1867. [[CrossRef](#)] [[PubMed](#)]
155. Merrill, C.A.; Jonsson, M.A.; Minthon, L.; Ejnell, H.; Silander, H.C.; Blennow, K.; Karlsson, M.; Nordlund, A.; Rolstad, S.; Warkentin, S.; et al. Vagus nerve stimulation in patients with Alzheimer’s disease: Additional follow-up results of a pilot study through 1 year. *J. Clin. Psychiatry* **2006**, *67*, 1171–1178. [[CrossRef](#)] [[PubMed](#)]
156. Vonck, K.; Raedt, R.; Naulaerts, J.; De Vogelaere, F.; Thiery, E.; Van Roost, D.; Aldenkamp, B.; Miatton, M.; Boon, P. Vagus nerve stimulation. 25 years later! What do we know about the effects on cognition? *Neurosci. Biobehav. Rev.* **2014**, *45*, 63–71. [[CrossRef](#)] [[PubMed](#)]
157. Follesa, P.; Biggio, F.; Gorini, G.; Caria, S.; Talani, G.; Dazzi, L.; Puligheddu, M.; Marrosu, F.; Biggio, G. Vagus nerve stimulation increases norepinephrine concentration and the gene expression of BDNF and bFGF in the rat brain. *Brain Res.* **2007**, *1179*, 28–34. [[CrossRef](#)]



158. Vida, G.; Pena, G.; Kanashiro, A.; Thompson-Bonilla, M.d.R.; Palange, D.; Deitch, E.A.; Ulloa, L. B2-Adrenoreceptors of regulatory lymphocytes are essential for vagal neuromodulation of the innate immune system. *FASEB J.* **2011**, *25*, 4476–4485. [[CrossRef](#)]
159. Bansal, V.; Ryu, S.Y.; Lopez, N.; Allexan, S.; Krzyzaniak, M.; Eliceiri, B.; Baird, A.; Coimbra, R. Vagal stimulation modulates inflammation through a ghrelin mediated mechanism in traumatic brain injury. *Inflammation* **2012**, *35*, 214–220. [[CrossRef](#)]
160. Borovikova, L.V.; Ivanova, S.; Zhang, M.; Yang, H.; Botchkina, G.I.; Watkins, L.R.; Wang, H.; Abumrad, N.; Eaton, J.W.; Tracey, K.J. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. *Nature* **2000**, *405*, 458–462. [[CrossRef](#)]
161. Corsi-Zuelli, F.M.G.; Brognara, F.; Quirino, G.F.S.; Hiroki, C.H.; Fais, R.S.; Del-Ben, C.M.; Ulloa, L.; Salgado, H.C.; Kanashiro, A. Neuroimmune interactions in schizophrenia: Focus on vagus nerve stimulation and activation of the alpha-7 nicotinic acetylcholine receptor. *Front. Immunol.* **2017**, *8*. [[CrossRef](#)]
162. Cunningham, J.T.; Mifflin, S.W.; Gould, G.G.; Frazer, A. Induction of c-Fos and delta-FosB immunoreactivity in rat brain by vagal nerve stimulation. *Neuropsychopharmacology* **2008**, *33*, 1884–1895. [[CrossRef](#)] [[PubMed](#)]
163. De Herdt, V.; Bogaert, S.; Bracke, K.R.; Raedt, R.; De Vos, M.; Vonck, K.; Boon, P. Effects of vagus nerve stimulation on pro- and anti-inflammatory cytokine induction in patients with refractory epilepsy. *J. Neuroimmunol.* **2009**, *214*, 104–108. [[CrossRef](#)] [[PubMed](#)]
164. Li, W.; Olshansky, B. Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation. *Heart Fail. Rev.* **2011**, *16*, 137–145. [[CrossRef](#)] [[PubMed](#)]
165. Majoie, H.J.M.; Rijkers, K.; Berfelo, M.W.; Hulsman, J.A.R.J.; Myint, A.; Schwarz, M.; Vles, J.S.H. Vagus nerve stimulation in refractory epilepsy: Effects on pro-and anti-inflammatory cytokines in peripheral blood. *Neuroimmunomodulation* **2011**, *18*, 52–56. [[CrossRef](#)]
166. Elzinga, B.M.; Bremner, J.D. Are the neural substrates of memory the final common pathway in posttraumatic stress disorder (PTSD)? *J. Affect. Disord.* **2002**, *70*, 1–17. [[CrossRef](#)]
167. Chen, S.-P.; Ayd, I.; de Moraisa, A.L.; Qina, T.; Zhenga, Y.; Sadeghiana, H.; Okaa, F.; Simon, B.; Eikermann-Haertera, K.; Ayataa, C. Vagus nerve stimulation inhibits cortical spreading depression. *Cephalgia* **2015**, *35*, 219–221. [[CrossRef](#)]
168. Ben-Menachem, E.; Hamberger, A.; Hedner, T.; Hammond, E.J.; Uthman, B.M.; Slater, J.; Treig, T.; Stefan, H.; Ramsay, R.E.; Wernicke, J.F.; et al. Effects of vagus nerve stimulation on amino acids and other metabolites in the CSF of patients with partial seizures. *Epilepsy Res.* **1995**, *20*, 221–227. [[CrossRef](#)]
169. Roosevelt, R.W.; Smith, D.C.; Clough, R.W.; Jensen, R.A.; Browning, R.A. Increased extracellular concentrations of norepinephrine in cortex and hippocampus following vagus nerve stimulation in the rat. *Brain* **2006**, *119*, 124–132. [[CrossRef](#)]
170. Oshinsky, M.L.; Murphy, A.L.; Hekierski, H.; Cooper, M.; Simon, B.J. Noninvasive vagus nerve stimulation as treatment for trigeminal allodynia. *Pain* **2014**, *155*, 1042–2037. [[CrossRef](#)]
171. Hays, S.A.; Khodaparast, N.; Hulse, D.R.; Ruiz, A.; Sloan, A.M.; Rennaker, R.L.; Kilgard, M.P. Vagus nerve stimulation during rehabilitative training improves functional recovery after intracerebral hemorrhage. *Stroke* **2014**, *45*, 3097–3100. [[CrossRef](#)]
172. Engineer, C.T.; Engineer, N.D.; Riley, J.R.; Seale, J.D.; Kilgard, M.P. Pairing speech sounds with vagus nerve stimulation drives stimulus-specific cortical plasticity. *Brain Stimul.* **2015**, *8*, 637–644. [[CrossRef](#)]
173. Engineer, N.D.; Riley, J.R.; Seale, J.D.; Vrana, W.A.; Shetake, J.A.; Sudanagunta, S.P.; Borland, M.S.; Kilgard, M.P. Reversing pathological neural activity using targeted plasticity. *Nature* **2011**, *470*, 101–104. [[CrossRef](#)] [[PubMed](#)]
174. Kim, H.J.; Shim, H.-J.; Kwak, M.Y.; An, Y.-H.; Kim, D.H.; Kim, Y.J. Feasibility and safety of transcutaneous vagus nerve stimulation paired with notched music therapy for the treatment of chronic tinnitus. *J. Audiol. Otol.* **2015**, *18*, 159–167.
175. Li, T.-T.; Wang, Z.-J.; Yang, S.-B.; Zhu, J.-H.; Zhang, S.-Z.; Cai, S.-J.; Ma, W.-H.; Zhang, D.-Q.; Mei, A.-G. Transcutaneous electrical stimulation at auricular acupoints innervated by auricular branch of vagus nerve pairing tone for tinnitus: Study protocol for a randomized controlled clinical trial. *Trials* **2015**, *16*, 1–9. [[CrossRef](#)] [[PubMed](#)]
176. Liu, A.; Zhao, F.-B.; Wang, J.; Lu, Y.F.; Tian, J.; Zhao, Y.; Gao, Y.; Hu, X.-J.; Liu, X.-Y.; Tan, J.; et al. Effects of vagus nerve stimulation on cognitive functioning in rats with cerebral ischemia reperfusion. *J. Transl. Med.* **2016**, *14*, 101. [[CrossRef](#)] [[PubMed](#)]



177. Hays, S.A. Enhancing rehabilitative therapies with vagus nerve stimulation. *Neurotherapeutics* **2016**, *13*, 382–394. [[CrossRef](#)]
178. Hays, S.A.; Ruiz, A.; Bethea, T.; Khodaparast, N.; Carmel, J.B.; Rennaker, R.L.; Kilgard, M.P. Vagus nerve stimulation during rehabilitative training enhances recovery of forelimb function after ischemic stroke in aged rats. *Neurobiol. Aging* **2016**, *43*, 111–118. [[CrossRef](#)]
179. Khodaparast, N.; Kilgard, M.P.; Casavant, R.; Ruiz, A.; Qureshi, I.; Ganzer, P.D.; Rennaker, R.L.; Hays, S.A. Vagus nerve stimulation during rehabilitative training improves forelimb recovery after chronic ischemic stroke in rats. *Neurorehabil. Neural Repair* **2015**, *30*, 676–684. [[CrossRef](#)]
180. Pruitt, D.T.; Schmid, A.N.; Kim, L.L.; Abe, C.M.; Trieu, J.L.; Choua, C. Vagus nerve stimulation delivered with motor training enhances recovery of function after traumatic brain injury. *J. Neurotrauma* **2016**, *33*, 871–879. [[CrossRef](#)]
181. Suthana, N.; Fried, I. Deep brain stimulation for enhancement of learning and memory. *Neuroimage* **2014**, *85*, 996–1002. [[CrossRef](#)]
182. Zuo, Y.; Smith, D.C.; Jensen, R.A. Vagus nerve stimulation potentiates hippocampal LTP in freely-moving rats. *Physiol. Behav.* **2007**, *90*, 583–589. [[CrossRef](#)] [[PubMed](#)]
183. McLaughlin, K.A.; Alves, S.; Sheridan, M.A. Vagal regulation and internalizing psychopathology among adolescents exposed to childhood adversity. *Dev. Psychobiol.* **2014**, *56*, 1036–1051. [[CrossRef](#)] [[PubMed](#)]
184. Li, M.; Zheng, C.; Sato, T.; Kawada, T.; Sugimachi, M.; Sunagawa, K. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. *Circulation* **2004**, *109*, 120–124. [[CrossRef](#)] [[PubMed](#)]
185. Meyers, R.; Pearlman, A.; Hyman, R. Beneficial effects of vagal stimulation and bradycardia during experimental acute myocardial ischemia. *Circulation* **1974**, *49*, 943–947. [[CrossRef](#)]
186. Kent, K.M.; Smith, E.R.; Redwood, D.R.; Epstein, S.E. Electrical stability of acutely ischemic myocardium: Influences to heart rate and vagal stimulation. *Circulation* **1973**, *47*, 291–298. [[CrossRef](#)]
187. Bohning, D.E.; Lomarev, M.P.; Denslow, S.; Nahas, Z.; Shastri, A.; George, M.S. Vagus Nerve Stimulation (VNS) synchronized BOLD-fMRI. *Radiology* **2001**, *36*, 470–479.
188. Chae, J.H.; Nahas, Z.; Lomarev, M.; Denslow, S.; Lorberbaum, J.P.; Bohning, D.E.; George, M.S. A review of functional neuroimaging studies of Vagus Nerve Stimulation (VNS). *J. Psychiatr. Res.* **2003**, *37*, 443–455. [[CrossRef](#)]
189. Smith, M.A.; Makino, S.; Kvetnansky, R.; Post, R.M. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNA in the hippocampus. *J. Neurosci.* **1995**, *15*, 1768–1777. [[CrossRef](#)]
190. Diamond, D.M.; Fleshner, M.; Ingersoll, N.; Rose, G.M. Psychological stress impairs spatial working memory: Relevance to electrophysiological studies of hippocampal function. *Behav. Neurosci.* **1996**, *110*, 661–672. [[CrossRef](#)]
191. Sapolsky, R.M.; Krey, L.; McEwen, B. Prolonged glucocorticoid exposure reduces hippocampal neuron number: Implications for aging. *J. Neurosci.* **1985**, *5*, 1221–1226. [[CrossRef](#)]
192. Woolley, C.S.; Gould, E.; McEwen, B.S. Exposure to excess glucocorticoids alters dendritic morphology of adult hippocampal pyramidal neurons. *Brain Res.* **1990**, *531*, 225–231. [[CrossRef](#)]
193. Elzinga, B.M.; Bermond, B.; van Dyck, R. The relationship between dissociative proneness and alexithymia. *Psychother. Psychosom.* **2002**, *71*, 104–111. [[CrossRef](#)]
194. Bremner, J.D.; Vermetten, E. The hippocampus and post-traumatic stress disorders. In *The Clinical Neurobiology of the Hippocampus: An Integrative View*; Bartsch, T., Ed.; Oxford University Press: Oxford, UK, 2012; pp. 262–272.
195. Bremner, J.D. Structural changes in the brain in depression and relationship to symptom recurrence. *CNS Spectr.* **2002**, *7*, 129–139. [[CrossRef](#)] [[PubMed](#)]
196. Bremner, J.D. Alterations in brain structure and function associated with posttraumatic stress disorder. *Semin. Clin. Neuropsychiatry* **1999**, *4*, 249–255.
197. Sheline, Y.I.; Wang, P.; Gado, M.; Csernansky, J.; Vannier, M. Hippocampal atrophy in recurrent major depression. *Proc. Natl. Acad. Sci. USA* **1996**, *93*, 3908–3913. [[CrossRef](#)]
198. LeDoux, J.E. *The Emotional Brain: The Mysterious Underpinnings of Emotional Life*; Simon & Schuster: New York, NY, USA, 1996.

199. Quirk, G.J. Memory for extinction of conditioned fear is long-lasting and persists following spontaneous recovery. *Learn. Mem.* **2002**, *9*, 402–407. [[CrossRef](#)] [[PubMed](#)]
200. Bremner, J.D.; Staib, L.; Kaloupek, D.; Southwick, S.M.; Soufer, R.; Charney, D.S. Neural correlates of exposure to traumatic pictures and sound in Vietnam combat veterans with and without posttraumatic stress disorder: A positron emission tomography study. *Biol. Psychiatry* **1999**, *45*, 806–816. [[CrossRef](#)]
201. Britton, J.C.; Phan, K.L.; Taylor, S.F.; Fig, L.M.; Liberzon, I. Corticolimbic blood flow in posttraumatic stress disorder during script-driven imagery. *Biol. Psychiatry* **2005**, *57*, 832–840. [[CrossRef](#)] [[PubMed](#)]
202. Shin, L.M.; McNally, R.J.; Kosslyn, S.M.; Thompson, W.L.; Rauch, S.L.; Alpert, N.M.; Metzger, L.J.; Lasko, N.B.; Orr, S.P.; Pitman, R.K. Regional cerebral blood flow during script-driven imagery in childhood sexual abuse-related PTSD: A PET investigation. *Am. J. Psychiatry* **1999**, *156*, 575–584. [[PubMed](#)]
203. Shin, L.M.; Kosslyn, S.M.; McNally, R.J.; Alpert, N.M.; Thompson, W.L.; Rauch, S.L.; Macklin, M.L.; Pitman, R.K. Visual imagery and perception in posttraumatic stress disorder: A positron emission tomographic investigation. *Arch. Gen. Psychiatry* **1997**, *54*, 233–237. [[CrossRef](#)]
204. Shin, L.M.; Orr, S.P.; Carson, M.A.; Rauch, S.L.; Macklin, M.L.; Lasko, N.B.; Peters, P.M.; Metzger, L.J.; Dougherty, D.D.; Cannistraro, P.A.; et al. Regional cerebral blood flow in the amygdala and medial prefrontal cortex during traumatic imagery in male and female Vietnam veterans with PTSD. *Arch. Gen. Psychiatry* **2004**, *61*, 168–176. [[CrossRef](#)] [[PubMed](#)]
205. Fonzo, G.A.; Simmons, A.N.; Thorp, S.R.; Norman, S.B.; Paulus, M.P.; Stein, M.B. Blood oxygenation level-dependent response to threat-related emotional faces in women with intimate-partner violence posttraumatic stress disorder. *Biol. Psychiatry* **2010**, *68*, 433–441. [[CrossRef](#)] [[PubMed](#)]
206. Phan, K.L.; Britton, J.C.; Taylor, S.F.; Fig, L.M.; Liberzon, I. Corticolimbic blood flow during nontraumatic emotional processing in posttraumatic stress disorder. *Arch. Gen. Psychiatry* **2006**, *63*, 184–192. [[CrossRef](#)] [[PubMed](#)]
207. Yang, P.; Wu, M.T.; Hsu, C.C.; Ker, J.H. Evidence of early neurobiological alternations in adolescents with posttraumatic stress disorder: A functional MRI study. *Neurosci. Lett.* **2004**, *370*, 13–18. [[CrossRef](#)] [[PubMed](#)]
208. Shin, L.M.; Whalen, P.J.; Pitman, R.K.; Bush, G.; Macklin, M.L.; Lasko, N.B.; Orr, S.P.; McInerney, S.C.; Rauch, S.L. An fMRI study of anterior cingulate function in posttraumatic stress disorder. *Biol. Psychiatry* **2001**, *50*, 932–942. [[CrossRef](#)]
209. Hopper, J.W.; Frewen, P.A.; van der Kolk, B.A.; Lanius, R.A. Neural correlates of reexperiencing, avoidance, and dissociation in PTSD: Symptom dimensions and emotion dysregulation in responses to script-driven trauma imagery. *J. Trauma. Stress* **2007**, *20*, 713–725. [[CrossRef](#)]
210. Hou, C.; Liu, J.; Wang, K.; Li, L.; Liang, M.; He, Z.; Liu, Y.; Zhang, Y.; Li, W.; Jiang, T. Brain responses to symptom provocation and trauma-related short-term memory recall in coal mining accident survivors with acute severe PTSD. *Brain Res.* **2007**, *1144*, 165–174. [[CrossRef](#)]
211. Lanius, R.A.; Williamson, P.C.; Hopper, J.; Densmore, M.; Boksman, K.; Gupta, M.A.; Neufeld, R.W.; Gati, J.S.; Menon, R.S. Recall of emotional states in posttraumatic stress disorder: An fMRI investigation. *Biol. Psychiatry* **2003**, *53*, 204–210. [[CrossRef](#)]
212. Lanius, R.A.; Williamson, P.C.; Densmore, M.; Boksman, K.; Gupta, M.A.; Neufeld, R.W.; Gati, J.S.; Menon, R.S. Neural correlates of traumatic memories in posttraumatic stress disorder: A functional MRI investigation. *Am. J. Psychiatry* **2001**, *158*, 1920–1922. [[CrossRef](#)]
213. Liberzon, I.; Taylor, S.F.; Amdur, R.; Jung, T.D.; Chamberlain, K.R.; Minoshima, S.; Koeppe, R.A.; Fig, L.M. Brain activation in PTSD in response to trauma-related stimuli. *Biol. Psychiatry* **1999**, *45*, 817–826. [[CrossRef](#)]
214. Liberzon, I.; Britton, J.C.; Phan, K.L. Neural correlates of traumatic recall in posttraumatic stress disorder. *Stress* **2003**, *6*, 151–156. [[CrossRef](#)] [[PubMed](#)]
215. Shin, L.M.; Wright, C.I.; Cannistraro, P.A.; Wedig, M.M.; McMullin, K.; Martis, B.; Macklin, M.L.; Lasko, N.B.; Cavanagh, S.R.; Krangel, T.S.; et al. A functional magnetic resonance imaging study of amygdala and medial prefrontal cortex responses to overtly presented fearful faces in posttraumatic stress disorder. *Arch. Gen. Psychiatry* **2005**, *62*, 273–281. [[CrossRef](#)] [[PubMed](#)]
216. Mayberg, H.S.; Liotti, M.; Brannan, S.K.; McGinnis, S.; Mahurin, R.K.; Jerabek, P.A.; Silva, J.A.; Tekell, J.L.; Martin, C.C.; Lancaster, J.L.; et al. Reciprocal limbic-cortical function and negative mood: Converging PET findings in depression and normal sadness. *Am. J. Psychiatry* **1999**, *156*, 675–682. [[PubMed](#)]

217. Sheline, Y.I.; Barcha, D.M.; Price, J.L.; Rundleb, M.M.; Vaishnavib, S.N.; Snyderb, A.Z.; Mintun, M.A.; Wanga, S.; Coalson, R.S.; Raichle, M.E. The default mode network and self-referential processes in depression. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 1942–1947. [[CrossRef](#)]
218. Drevets, W.C.; Price, J.L.; Simpson, J.R.J.; Todd, R.D.; Reich, T.; Vannier, M.; Raichle, M.E. Subgenual prefrontal cortex abnormalities in mood disorders. *Nature* **1997**, *386*, 824–827. [[CrossRef](#)]
219. Simmons, A.N.; Paulus, M.P.; Thorp, S.R.; Matthews, S.C.; Norman, S.B.; Stein, M.B. Functional activation and neural networks in women with posttraumatic stress disorder related to intimate partner violence. *Biol. Psychiatry* **2008**, *64*, 681–690. [[CrossRef](#)]
220. Rauch, S.L.; van der Kolk, B.A.; Fisler, R.E.; Alpert, N.M.; Orr, S.P.; Savage, C.R.; Fischman, A.J.; Jenike, M.A.; Pitman, R.K. A symptom provocation study of posttraumatic stress disorder using positron emission tomography and script-driven imagery. *Arch. Gen. Psychiatry* **1996**, *53*, 380–387. [[CrossRef](#)]
221. Admon, R.; Lubin, G.; Stern, O.; Rosenberg, K.; Sela, L.; Ben-Ami, H.; Hendler, T. Human vulnerability to stress depends on amygdala's predisposition and hippocampal plasticity. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 14120–14125. [[CrossRef](#)]
222. Bremner, J.D.; Vermetten, E.; Schmahl, C.; Vaccarino, V.; Vythilingam, M.; Afzal, N.; Grillon, C.; Charney, D.S. Positron emission tomographic imaging of neural correlates of a fear acquisition and extinction paradigm in women with childhood sexual abuse-related posttraumatic stress disorder. *Psychol. Med.* **2005**, *35*, 791–806. [[CrossRef](#)]
223. Rauch, S.L.; Shin, L.M.; Wright, C.I. Neuroimaging studies of amygdala function in anxiety disorders. *Ann. N. Y. Acad. Sci.* **2003**, *985*, 389–410. [[CrossRef](#)]
224. Protopopescu, X.; Pan, H.; Tuescher, O.; Cloitre, M.; Goldstein, M.; Engelien, W.; Epstein, J.; Yang, Y.; Gorman, J.; LeDoux, J.; et al. Differential time courses and specificity of amygdala activity in posttraumatic stress disorder subjects and normal control subjects. *Biol. Psychiatry* **2005**, *57*, 464–473. [[CrossRef](#)] [[PubMed](#)]
225. Chung, Y.A.; Kim, S.H.; Chung, S.K.; Chae, J.H.; Yang, D.W.; Sohn, H.S.; Jeong, J. Alterations in cerebral perfusion in posttraumatic stress disorder patients without re-exposure to accident-related stimuli. *Clin. Neurophysiol.* **2006**, *117*, 637–642. [[CrossRef](#)]
226. Felmingham, K.L.; Williams, L.M.; Kemp, A.H.; Rennie, C.; Gordon, E.; Bryant, R.A. Anterior cingulate activity to salient stimuli is modulated by autonomic arousal in posttraumatic stress disorder. *Psychiatry Res.* **2009**, *173*, 59–62. [[CrossRef](#)] [[PubMed](#)]
227. Semple, W.E.; Goyer, P.; McCormick, R.; Donovan, B.; Muzic, R.F.; Ruge, L.; McCutcheon, K.; Lewis, C.; Liebling, D.; Kowaliv, S.; et al. Higher brain blood flow at amygdala and lower frontal cortex blood flow in PTSD patients with comorbid cocaine and alcohol abuse compared to controls. *Psychiatry* **2000**, *63*, 65–74. [[CrossRef](#)] [[PubMed](#)]
228. Bryant, R.A.; Felmingham, K.L.; Kemp, A.H.; Barton, M.; Peduto, A.S.; Rennie, C.; Gordon, E.; Williams, L.M. Neural networks of information processing in posttraumatic stress disorder: A functional magnetic resonance imaging study. *Biol. Psychiatry* **2005**, *58*, 111–118. [[CrossRef](#)]
229. Armony, J.L.; Corbo, V.; Clement, M.H.; Brunet, A. Amygdala response in patients with acute PTSD to masked and unmasked emotional facial expressions. *Am. J. Psychiatry* **2005**, *162*, 1961–1963. [[CrossRef](#)]
230. Bryant, R.A.; Kemp, A.H.; Felmingham, K.L.; Liddell, B.; Olivieri, G.; Peduto, A.; Gordon, E.; Williams, L.M. Enhanced amygdala and medial prefrontal activation during nonconscious processing of fear in posttraumatic stress disorder: An fMRI study. *Hum. Brain Mapp.* **2008**, *29*, 517–523. [[CrossRef](#)]
231. Kemp, A.H.; Felmingham, K.; Das, P.; Hughes, G.; Peduto, A.S.; Bryant, R.A.; Williams, L.M. Influence of comorbid depression on fear in posttraumatic stress disorder: An fMRI study. *Psychiatry Res.* **2007**, *155*, 265–269. [[CrossRef](#)]
232. Kemp, A.H.; Felmingham, K.L.; Falconer, E.; Liddell, B.J.; Bryant, R.A.; Williams, L.M. Heterogeneity of non-conscious fear perception in posttraumatic stress disorder as a function of physiological arousal: An fMRI study. *Psychiatry Res.* **2009**, *174*, 158–161. [[CrossRef](#)]
233. Rauch, S.L.; Whalen, P.J.; Shin, L.M.; McInerney, S.C.; Macklin, M.L.; Lasko, N.B.; Orr, S.P.; Pitman, R.K. Exaggerated amygdala response to masked facial stimuli in posttraumatic stress disorder: A functional MRI study. *Biol. Psychiatry* **2000**, *47*, 769–776. [[CrossRef](#)]
234. Brohawn, K.H.; Offringa, R.; Pfaff, D.L.; Hughes, K.C.; Shin, L.M. The neural correlates of emotional memory in posttraumatic stress disorder. *Biol. Psychiatry* **2010**, *68*, 1023–1030. [[CrossRef](#)] [[PubMed](#)]

235. Brunetti, M.; Sepede, G.; Mingoia, G.; Catani, C.; Ferretti, A.; Merla, A.; Del Gratta, C.; Romani, G.L.; Babiloni, C. Elevated response of human amygdala to neutral stimuli in mild post traumatic stress disorder: Neural correlates of generalized emotional response. *Neuroscience* **2010**, *168*, 670–679. [[CrossRef](#)] [[PubMed](#)]
236. Pissioti, A.; Frans, O.; Fernandez, M.; Von Knorring, L.; Fischer, H.; Fredrikson, M. Neurofunctional correlates of posttraumatic stress disorder: A PET symptom provocation study. *Eur. Arch. Psychiatry Clin. Neurosci.* **2002**, *252*, 68–75. [[CrossRef](#)] [[PubMed](#)]
237. Milad, M.R.; Pitman, R.K.; Ellis, C.B.; Gold, A.L.; Shin, L.M.; Lasko, N.B.; Zeidan, M.A.; Handwerker, K.; Orr, S.P.; Rauch, S.L. Neurobiological basis of failure to recall extinction memory in posttraumatic stress disorder. *Biol. Psychiatry* **2009**, *66*, 1075–1082. [[CrossRef](#)]
238. Drevets, W.C.; Raichle, M.E. Neuroanatomical circuits in depression: Implications for treatment mechanisms. *Psychopharmacol. Bull.* **1992**, *28*, 261–274.
239. Drevets, W.C.; Price, J.L.; Bardgett, M.E.; Reich, T.; Todd, R.D.; Raichle, M.E. Glucose metabolism in the amygdala in depression: Relationship to diagnostic subtype and plasma cortisol levels. *Pharmacol. Biochem. Behav.* **2002**, *71*, 431–447. [[CrossRef](#)]
240. Saxena, S.; Brody, A.L.; Ho, M.L.; Zohrabi, N.; Maidment, K.M.; Baxter, L.R. Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. *Am. J. Psychiatry* **2003**, *160*, 522–532. [[CrossRef](#)]
241. Sheline, Y.I.; Barch, D.M.; Donnelly, J.M.; Ollinger, J.M.; Snyder, A.Z.; Mintun, M.A. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: An fMRI study. *Biol. Psychiatry* **2001**, *50*, 651–658. [[CrossRef](#)]
242. Bremner, J.D.; Campanella, C. Effects of psychotherapy for psychological trauma on PTSD symptoms and the brain. In *Posttraumatic Stress Disorder: From Neurobiology to Treatment*; Bremner, J.D., Ed.; John Wiley & Sons: Hoboken, NJ, USA, 2016; pp. 413–420.
243. Vermetten, E.; Vythilingam, M.; Southwick, S.M.; Charney, D.S.; Bremner, J.D. Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. *Biol. Psychiatry* **2003**, *54*, 693–702. [[CrossRef](#)]
244. Letizia, B.; Andrea, F.; Paolo, C. Neuroanatomical changes after eye movement desensitization and reprocessing (EMDR) treatment in posttraumatic stress disorder. *J. Neuropsychiatry Clin. Neurosci.* **2007**, *19*, 475–476. [[CrossRef](#)]
245. Bremner, J.D.; Mletzko, T.; Welter, S.; Quinn, S.; Williams, C.; Brummer, M.; Siddiq, S.; Reed, L.; Heim, C.M.; Nemeroff, C.B. Effects of phenytoin on memory, cognition and brain structure in posttraumatic stress disorder: A pilot study. *J. Psychopharmacol.* **2005**, *19*, 159–165. [[CrossRef](#)] [[PubMed](#)]
246. Fani, N.; Kitayama, N.; Ashraf, A.; Reed, L.; Afzal, N.; Jawed, F.; Bremner, J.D. Neuropsychological functioning in patients with posttraumatic stress disorder following short-term paroxetine treatment. *Psychopharmacol. Bull.* **2009**, *42*, 53–68. [[PubMed](#)]
247. Fani, N.; Ashraf, A.; Afzal, N.; Jawed, F.; Kitayama, N.; Reed, L.; Bremner, J.D. Increased neural response to trauma scripts in posttraumatic stress disorder following paroxetine treatment: A pilot study. *Neurosci. Lett.* **2011**, *491*, 196–201. [[CrossRef](#)] [[PubMed](#)]
248. Brody, A.L.; Saxena, S.; Stoessel, P.; Gillies, L.A.; Fairbanks, L.A.; Alborzian, S.; Phelps, M.E.; Huang, S.C.; Wu, H.M.; Ho, M.L.; et al. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: Preliminary findings. *Arch. Gen. Psychiatry* **2001**, *58*, 631–640. [[CrossRef](#)] [[PubMed](#)]
249. Bremner, J.D.; Vythilingam, M.; Vermetten, E.; Charney, D.S. Effects of antidepressant treatment on neural correlates of emotional and neutral declarative verbal memory in depression. *J. Affect. Disord.* **2007**, *101*, 99–111. [[CrossRef](#)]
250. Drevets, W.C.; Bogers, W.; Raichle, M.E. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. *Eur. Neuropsychopharmacol.* **2002**, *12*, 527–544. [[CrossRef](#)]
251. Kennedy, S.H.; Evans, K.R.; Kruger, S.; Mayberg, H.S.; Meyer, J.H.; McCann, S.; Arifuzzman, A.I.; Houle, S.; Vaccarino, F.J. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. *Am. J. Psychiatry* **2001**, *158*, 899–905. [[CrossRef](#)]



252. Vythilingam, M.; Vermetten, E.; Anderson, G.M.; Luckenbaugh, D.; Anderson, E.R.; Snow, J.; Staib, L.H.; Charney, D.S.; Bremner, J.D. Hippocampal volume, memory and cortisol status in major depressive disorder: Effects of treatment. *Biol. Psychiatry* **2004**, *56*, 101–112. [[CrossRef](#)]
253. Henry, T.R. Therapeutic mechanisms of vagus nerve stimulation. *Neurology* **2002**, *59*, S3–S14. [[CrossRef](#)]
254. Henry, T.R.; Bakay, R.A.; Votaw, J.R.; Pennell, P.B.; Epstein, C.M.; Faber, T.L.; Grafton, S.T.; Hoffman, J.M. Brain blood flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy: I. Acute effects at high and low levels of stimulation. *Epilepsia* **1998**, *39*, 983–990. [[CrossRef](#)]
255. Conway, C.R.; Sheline, Y.I.; Chibnall, J.T.; Bucholz, R.D.; Price, J.L.; Gangwani, S.; Mintun, M.A. Brain blood-flow change with acute vagus nerve stimulation in treatment-refractory major depressive disorder. *Brain Stimul.* **2012**, *5*, 163–171. [[CrossRef](#)]
256. Fang, J.; Egorova, N.; Rong, P.; Liu, J.; Hong, Y.; Fan, Y.; Wang, X.; Wang, H.; Yu, Y.; Ma, Y.; et al. Early cortical biomarkers of longitudinal transcutaneous vagus nerve stimulation treatment success in depression. *Neuroimage Clin.* **2017**, *14*, 105–111. [[CrossRef](#)]
257. Liu, J.; Fang, J.; Wang, Z.; Rong, P.; Hong, Y.; Fan, Y.; Wang, X.; Park, J.; Jin, Y.; Liu, C.; et al. Transcutaneous vagus nerve stimulation modulates amygdala functional connectivity in patients with depression. *J. Affect. Disord.* **2016**, *205*, 319–326. [[CrossRef](#)]
258. Lomarev, M.; Denslow, S.; Nahas, Z.; Chae, J.-H.; George, M.S.; Bohning, D.E. Vagus nerve stimulation (VNS): Synchronized BOLD fMRI suggests that VNS in depressed adults has frequency and/or dose dependent effects at rest and during a simple task. *J. Psychiatr. Res.* **2002**, *36*, 219–227. [[CrossRef](#)]
259. Van Laere, K.; Vonck, K.; Boon, P.; Versijpt, J.; Dierckx, R. Perfusion SPECT changes after acute and chronic vagus nerve stimulation in relation to prestimulus condition and long-term efficacy. *J. Nucl. Med.* **2002**, *43*, 733–744. [[PubMed](#)]
260. Bremner, J.D.; Wittbrodt, M.T.; Gurel, N.Z.; Nye, J.; Alam, A.; Vaccarino, V.; Ladd, S.L.; Shallenberger, L.H.; Huang, M.; Ko, Y.-Y.; et al. Brain correlates of non-invasive Vagal Nerve Stimulation in stress. In Proceedings of the NYC Neuromodulation/NANS Conference, New York, NY, USA, 24–26 August 2018; p. 14.
261. Bremner, J.D.; Rapaport, M.H. Vagus Nerve Stimulation: Back to the future. *Am. J. Psychiatry* **2017**, *174*, 609–610. [[CrossRef](#)] [[PubMed](#)]
262. Yakunina, N.; Kim, S.S.; Nam, E.-C. Optimization of transcutaneous vagus nerve stimulation using functional MRI. *Neuromodulation* **2017**, *20*, 290–300. [[CrossRef](#)]
263. Redgrave, J.; Day, D.; Leung, H.; Ali, A.; Lindert, R.; Majid, A. Safety and tolerability of transcutaneous vagus nerve stimulation in humans: A systematic review. *Brain Stimul.* **2018**, *11*, 1225–1238. [[CrossRef](#)] [[PubMed](#)]
264. Ben-Menachem, E.; Revesz, D.; Simon, B.J.; Silberstein, S. Surgically implanted and non-invasive vagus nerve stimulation: A review of efficacy, safety and tolerability. *Eur. J. Neurol.* **2015**, *22*, 1260–1268. [[CrossRef](#)]
265. Nonis, R.; D’Ostilio, K.; Schoenen, J.; Magis, D. Evidence of activation of vagal afferents by non-invasive vagus nerve stimulation: An electrophysiological study in healthy volunteers. *Cephalgia* **2017**, *37*, 1285–1293. [[CrossRef](#)]
266. Usami, K.; Kawai, K.; Sonoo, M.; Saito, N. Scalp-recorded evoked potentials as a marker for afferent nerve impulse in clinical vagus nerve stimulation. *Brain Stimul.* **2013**, *6*, 615–623. [[CrossRef](#)] [[PubMed](#)]
267. Yoo, P.B.; Lubock, N.B.; Hincapie, J.G.; Ruble, S.B.; Hamann, J.J.; Grill, W.M. High-resolution measurement of electrically-evoked vagus nerve activity in the anesthetized dog. *J. Neural Eng.* **2013**, *10*. [[CrossRef](#)] [[PubMed](#)]
268. Fallgatter, A.J.; Neuhauser, B.; Herrmann, M.J.; Ehlis, A.-C.; Wagener, A.; Scheuerpflug, P.; Reiners, K.; Riederer, P. Far field potentials from the brain stem after transcutaneous vagus nerve stimulation. *J. Neural Transm.* **2003**, *110*, 1437–1443. [[CrossRef](#)] [[PubMed](#)]
269. Frangos, E.; Ellrich, E.; Komisaruk, B.R. Non-invasive access to the vagus nerve central projections via electrical stimulation of the external ear: fMRI evidence in humans. *Brain Stimul.* **2015**, *8*, 624–636. [[CrossRef](#)]
270. Badran, B.W.; Dowdle, L.T.; Mithoefer, O.J.; LaBate, N.T.; Coatsworth, J.; Brown, J.C.; DeVries, W.H.; Austelle, C.W.; McTeague, L.M.; George, M.S. Neurophysiologic effects of transcutaneous auricular vagus nerve stimulation (taVNS) via electrical stimulation of the tragus: A concurrent taVNS/fMRI study and review. *Brain Stimul.* **2018**, *11*, 492–500. [[CrossRef](#)]
271. Frangos, E.; Komisaruk, B.R. Access to vagal projections via cutaneous electrical stimulation of the neck: fMRI evidence in healthy humans. *Brain Stimul.* **2017**, *10*, 19–27. [[CrossRef](#)]



272. Clancy, J.A.; Mary, D.A.; Witte, K.K.; Greenwood, J.P.; Deuchars, S.A.; Deuchars, J. Non-invasive vagus nerve stimulation in healthy humans reduces sympathetic nerve activity. *Brain Stimul.* **2014**, *7*, 871–877. [[CrossRef](#)]
273. Badran, B.W.; Mithoefer, O.J.; Summer, C.E.; LaBate, N.T.; Glusman, C.E.; Badran, A.W.; DeVries, W.H.; Summers, P.M.; Austelle, C.W.; McTeague, L.M.; et al. Short trains of transcutaneous auricular vagus nerve stimulation (taVNS) have parameter-specific effects on heart rate. *Brain Stimul.* **2018**, *11*, 699–708. [[CrossRef](#)]
274. Warren, C.M.; Tona, K.D.; Ouwerkerk, L.; van Paridon, J.; Poletiek, F.; van Steenberg, H.; Bosch, J.A.; Nieuwenhuis, S. The neuromodulatory and hormonal effects of transcutaneous vagus nerve stimulation as evidenced by salivary alpha amylase, salivary cortisol, pupil diameter, and the P3 event-related potential. *Brain Stimul.* **2019**, *12*, 635–642. [[CrossRef](#)]
275. Burger, A.M.; Verkuil, B.; Fenlon, H.; Thijs, L.; Cools, H.C.; Miller, I.; Vervliet, B.; Van Diest, I. Mixed evidence for the potential of non-invasive transcutaneous vagal nerve stimulation to improve the extinction and retention of fear. *Behav. Res. Ther.* **2017**, *97*, 64–74. [[CrossRef](#)]
276. Verkuil, B.; Burger, A.M. Transcutaneous vagus nerve stimulation does not affect attention to fearful faces in high worriers. *Behav. Res. Ther.* **2019**, *113*, 25–31. [[CrossRef](#)] [[PubMed](#)]
277. Gurel, N.Z.; Huang, M.; Wittbrodt, M.T.; Jung, H.; Ladd, S.L.; Shandhi, M.H.; Ko, Y.-A.; Shallenberger, L.; Nye, J.A.; Pearce, B.; et al. Quantifying acute physiological biomarkers of transcutaneous cervical vagal nerve stimulation in the context of psychological stress. *Brain Stimul.* **2020**, *13*, 47–59. [[CrossRef](#)] [[PubMed](#)]
278. Gurel, N.Z.; Gazi, A.H.; Scott, K.L.; Wittbrodt, M.T.; Shah, A.J.; Vaccarino, V.; Bremner, J.D.; Inan, O.T. Timing considerations for noninvasive Vagal Nerve Stimulation in clinical studies. *AMIA Annu. Symp. Proc.* **2020**, *2019*, 1061–1070. [[PubMed](#)]
279. Gurel, N.Z.; Wittbrodt, W.T.; Jung, H.; Ladd, S.L.; Shah, A.J.; Vaccarino, V.; Bremner, J.D.; Inan, O.T. Automatic detection of target engagement in transcutaneous cervical Vagal Nerve Stimulation for traumatic stress triggers. *IEEE J. Biomed. Health Inform.* **2020**, *24*, 1917–1925. [[CrossRef](#)] [[PubMed](#)]
280. Brock, C.; Brock, B.; Aziz, Q.; Møller, H.J.; Pfeiffer Jensen, M.; Drewes, A.M.; Farmer, A.D. Transcutaneous cervical vagal nerve stimulation modulates cardiac vagal tone and tumor necrosis factor-alpha. *Neurogastroenterol. Motil.* **2017**, *29*, e12999. [[CrossRef](#)]
281. Lerman, I.; Hauger, R.; Sorkin, L.; Proudfoot, J.; Davis, B.; Huang, A.; Lam, K.; Simon, B.; Baker, D.G. Noninvasive transcutaneous vagus nerve stimulation decreases whole blood culture-derived cytokines and chemokines: A randomized, blinded, healthy control pilot trial. *Neuromodulation* **2016**, *19*, 283–290. [[CrossRef](#)]
282. Tarn, J.; Legg, S.; Mitchell, S.; Simon, B.; Ng, W.-F. The effects of noninvasive vagus nerve stimulation on fatigue and immune responses in patients with primary Sjögren’s Syndrome. *Neuromodulation* **2019**, *22*, 580–585. [[CrossRef](#)]
283. Milev, R.V.; Giacobbe, P.; Kennedy, S.H.; Blumberger, D.M.; Daskalakis, Z.J.; Downar, J.; Modirrousta, M.; Patry, S.; Vila-Rodriguez, F.; Lam, R.W.; et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 4. Neurostimulation Treatments. *Can. J. Psychiatry* **2016**, *61*, 561–575. [[CrossRef](#)]
284. Feldman, R.L.; Dunner, D.L.; Muller, J.S.; Stone, D.A. Medicare patient experience with vagus nerve stimulation for treatment-resistant depression. *J. Med. Econ.* **2013**, *16*, 63–74. [[CrossRef](#)]
285. Hasan, A.; Wolff-Menzler, C.; Pfeiffer, S.; Falkai, P.; Weidinger, E.; Jobst, A.; Hoell, I.; Malchow, B.; Yeganeh-Doost, P.; Strube, W.; et al. Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: A bicentric randomized controlled pilot study. *Eur. Arch. Psychiatry Clin. Neurosci.* **2015**, *256*, 589–600. [[CrossRef](#)]
286. D’Urso, G.; Brunoni, A.R.; Mazzaferro, M.P.; Anastasia, A.; de Bartolomeis, A.; Mantovani, A. Transcranial direct current stimulation for obsessive-compulsive disorder: A randomized, controlled, partial crossover trial. *Depress. Anxiety* **2016**, *33*, 1132–1140. [[CrossRef](#)] [[PubMed](#)]
287. Rong, P.; Liu, J.; Wang, L.; Liu, R.; Fang, J.; Zhao, J.; Zhao, Y.; Wang, H.; Vangel, M.; Sun, S.; et al. Effect of transcutaneous auricular vagus nerve stimulation on major depressive disorder: A nonrandomized controlled pilot study. *J. Affect. Disord.* **2016**, *195*, 172–179. [[CrossRef](#)] [[PubMed](#)]
288. Lamb, D.G.; Porges, E.C.; Lewis, G.F.; Williamson, J.B. Non-invasive Vagal Nerve Stimulation effects on hyperarousal and autonomic state in patients with posttraumatic stress disorder and history of mild traumatic brain injury: Preliminary evidence. *Front. Med.* **2017**, *4*, 124. [[CrossRef](#)] [[PubMed](#)]

289. George, M.S.; Ward, H.E.; Ninan, P.T.; Pollack, M.; Nahas, Z.; Anderson, B.; Kose, S.; Howland, R.H.; Goodman, W.K.; Ballenger, J.C. A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. *Brain Stimul.* **2008**, *1*, 112–121. [[CrossRef](#)] [[PubMed](#)]
290. Barbanti, P.; Grazi, L.; Egeo, G.; Padovan, A.; Liebler, E.; Bussone, G. Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: An open-label study. *J. Headache Pain* **2015**, *16*, 61. [[CrossRef](#)]
291. Nesbitt, A.D.; Marin, J.C.A.; Tomkins, E.; Rutledge, M.H.; Goadsby, P.J. Non-invasive vagus nerve stimulation for the treatment of cluster headache: A case series. *J. Headache Pain* **2013**, *14*. [[CrossRef](#)]
292. Gaul, C.; Magis, D.; Liebler, E.J.; Straube, A. Effects of non-invasive vagus nerve stimulation on attack frequency over time and expanded response rates in patients with chronic cluster headache: A post hoc analysis of the randomized, controlled PREVA Study. *J. Headache Pain* **2017**, *18*, 22. [[CrossRef](#)]
293. Rosell, J.; Colominas, J.; Riu, P.; Pallas-Areny, R.; Webster, J.G. Skin impedance from 1 Hz to 1 MHz. *IEEE Trans. Biomed. Eng.* **1988**, *35*, 649–651. [[CrossRef](#)]
294. Gazi, A.H.; Gurel, N.Z.; Richardson, J.L.S.; Wittbrodt, M.T.; Shah, A.J.; Vaccarino, V.; Bremner, J.D.; Inan, O.T. Investigating digital cardiovascular biomarker responses to transcutaneous cervical vagus nerve stimulation: State-space modeling, prediction, and simulation. *JMIR hHealth uHealth* **2020**. [[CrossRef](#)]
295. Wittbrodt, M.T.; Gurel, N.Z.; Nye, J.A.; Ladd, S.; Shandhi, M.M.H.; Huang, M.; Shah, A.J.; Pearce, B.D.; Alam, Z.S.; Rapaport, M.H.; et al. Non-invasive vagal nerve stimulation decreases brain activity during trauma scripts. *Brain Stimul.* **2020**, *13*, 1333–1348. [[CrossRef](#)]
296. Pimple, P.; Lima, B.B.; Hammadah, M.; Wilmot, K.; Ramadan, R.; Levantsevych, O.; Sullivan, S.; Kim, J.H.; Kaseer, B.; Shah, A.J.; et al. Psychological distress and subsequent cardiovascular events in individuals with coronary artery disease. *J. Am. Hear. Assoc.* **2019**, *8*, e011866. [[CrossRef](#)] [[PubMed](#)]
297. Lima, B.B.; Hammadah, M.; Pearce, B.D.; Shah, A.; Moazzami, K.; Kim, J.H.; Sullivan, S.; Levantsevych, O.; Lewis, T.T.; Weng, L.; et al. Association of posttraumatic stress disorder with mental stress-induced myocardial ischemia in adults after myocardial infarction. *JAMA Netw. Open* **2020**, *3*, e202734. [[CrossRef](#)] [[PubMed](#)]
298. Pimple, P.; Shah, A.; Rooks, C.; Bremner, J.D.; Nye, J.; Ibeanu, I.; Murrah, N.; Shallenberger, L.; Kelley, M.; Raggi, P.; et al. Association between anger and mental stress-induced myocardial ischemia. *Am. Heart J.* **2015**, *169*, 115–121. [[CrossRef](#)] [[PubMed](#)]
299. Gurel, N.Z.; Mobashir, H.S.; Bremner, J.D.; Vaccarino, V.; Ladd, S.L.; Shah, A.; Inan, O.T. Toward closed-loop transcutaneous vagus nerve stimulation using peripheral cardiovascular physiological biomarkers: A proof-of-concept study. *IEEE Body Sens. Netw.* **2018**. [[CrossRef](#)]
300. Szeska, C.; Richter, J.; Wendt, J.; Weymar, M.; Hamm, A.O. Promoting long-term inhibition of human fear responses by non-invasive transcutaneous vagus nerve stimulation during extinction training. *Sci. Rep.* **2020**, *10*, 1529. [[CrossRef](#)] [[PubMed](#)]

